filgotinib vs tofacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: JAK · full Rheumatoid Arthritis pipeline

filgotinib · Jyseleca

Marketed by Gilead Sciences and partners

Phase 3 in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02873936 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).

Next expected readout: April 2029 · NCT06687551 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)

Result source: NCT02889796

tofacitinib · Xeljanz

Marketed by Pfizer

Approved in Rheumatoid ArthritisSmall molecule (pan-JAK inhibitor)
Weak signal

NCT01262118 · Phase 1 · completed

This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.

Next expected readout: January 2027 · NCT06945666 (registry estimate)

Reported efficacy

High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline; High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6; Cholesterol Ester Production Rate at Baseline; Cholesterol Ester Production Rate at Week 6: HDL cholesterol in the rheumatoid arthritis cohort on tofacitinib 10 mg twice daily: mean 54.30 mg/dL (SD 12.52) at baseline and 62.34 mg/dL (SD 15.24) at Week 6. The untreated healthy-volunteer cohort (63.43 mg/dL at baseline) is a reference group only. No statistical analysis is posted. (not_applicable)

Result source: NCT01262118

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfilgotinibtofacitinib
ACR2076.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181
52.7% vs 31.2%+21.5 vs placebo5 mg · wk 24 · n 311NCT00856544
273 other results
  • 51.5% vs 28.3% 5 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 51.5% vs 25.3% 5 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 59.8% vs 26.7% 5 mg · wk 12 · n 241 · Phase 3 · primary NCT00814307
  • 41.7% vs 24.4% 5 mg · wk 12 · n 132 · Phase 3 · primary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00856544
  • 52.5% vs 28.3% 10 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 61.8% vs 25.3% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 65.7% vs 26.7% 10 mg · wk 12 · n 242 · Phase 3 · primary NCT00814307
  • 48.1% vs 24.4% 10 mg · wk 12 · n 133 · Phase 3 · primary NCT00960440
  • 52.7% vs 31.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 50.8% vs 25.5% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 56.3% vs 27.4% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 60.7% vs 26.4% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 56.3% vs 27.3% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 56.9% vs 25.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 54.0% vs 26.1% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 46.5% vs 21.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 38.6% vs 22.9% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 41.2% vs 16.0% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 41.4% vs 16.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 42.4% vs 27.5% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 29.6% vs 11.8% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 10.9% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 27.7% vs 16.7% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 57.9% vs 25.5% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 64.7% vs 27.4% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 58.7% vs 26.4% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 66.3% vs 27.3% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 60.7% vs 25.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 64.4% vs 26.1% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 52.1% vs 21.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 48.5% vs 22.9% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 45.9% vs 16.0% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 52.1% vs 16.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 44.4% vs 27.5% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 39.2% vs 11.8% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 32.3% vs 10.9% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 32.8% vs 16.7% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 49.5% vs 49.3% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 67.8% vs 51.1% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 47.2% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 72.1% vs 55.4% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 68.8% vs 47.3% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 71.3% vs 50.5% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 46.7% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 69.9% vs 51.6% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 65.0% vs 45.1% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 63.6% vs 42.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 21.2% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 71.6% vs 51.1% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 47.2% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 73.6% vs 55.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 66.2% vs 47.3% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 76.1% vs 50.5% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 66.0% vs 46.7% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 77.9% vs 51.6% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 62.2% vs 45.1% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 71.6% vs 42.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 58.3% vs 21.2% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 73.1% vs 15.4% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT00687193
  • 61.2% vs 23.7% 5 mg · wk 12 · n 49 · Phase 2 · primary NCT00550446
  • 96.3% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 56.3% vs 36.2% 5 mg · wk 12 · n 71 · Phase 2 · primary NCT00413660
  • 70.5% vs 29.2% 5 mg BID · wk 6 · n 61 · Phase 2 · primary NCT00147498
  • 84.9% vs 15.4% 10 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 72.1% vs 23.7% 10 mg · wk 12 · n 61 · Phase 2 · primary NCT00550446
  • 80.8% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · primary NCT00603512
  • 58.1% vs 36.2% 10 mg · wk 12 · n 74 · Phase 2 · primary NCT00413660
  • 76.8% vs 29.2% 30 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 56.3% vs 36.2% 20 mg · wk 12 · n 80 · Phase 2 · primary NCT00413660
  • 90.7% vs 15.4% 15 mg · wk 12 · n 54 · Phase 2 · primary NCT00687193
  • 71.9% vs 23.7% 15 mg · wk 12 · n 57 · Phase 2 · primary NCT00550446
  • 56% vs 36.2% 15 mg · wk 12 · n 75 · Phase 2 · primary NCT00413660
  • 81.2% vs 29.2% 15 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 67.9% vs 15.4% 3 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 45.1% vs 23.7% 3 mg · wk 12 · n 51 · Phase 2 · primary NCT00550446
  • 77.8% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 55.9% vs 36.2% 3 mg · wk 12 · n 68 · Phase 2 · primary NCT00413660
  • 37.7% vs 15.4% 1 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 31.5% vs 23.7% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT00550446
  • 64.3% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · primary NCT00603512
  • 47.1% vs 36.2% 1 mg · wk 12 · n 70 · Phase 2 · primary NCT00413660
  • 57.1% vs 47.1% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 69.4% vs 32.4% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 57.7% vs 47.1% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 67.3% vs 35.3% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 53.5% vs 43.1% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 57.1% vs 23.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 67.3% vs 11.5% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 63.3% vs 27.1% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 96.3% vs 21.4% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.9% vs 33.3% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 50% vs 28.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 63.3% vs 25.4% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 57.8% vs 37.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 61.5% vs 9.6% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 40.8% vs 27.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 88.9% vs 10.7% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 46.5% vs 24.6% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 63.9% vs 30.8% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 34.6% vs 5.8% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 32.6% vs 15.3% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 63.0% vs 10.7% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 31.0% vs 15.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 50.8% vs 20% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 29.6% vs 3.6% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 27.9% vs 12.3% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 73.8% vs 47.1% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 66.2% vs 47.1% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 73.8% vs 32.4% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 62.2% vs 47.1% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 70.5% vs 35.3% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 64.9% vs 43.1% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 86.8% vs 11.5% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 65.6% vs 27.1% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 56.8% vs 33.3% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 55.4% vs 37.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 81.1% vs 9.6% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 46.0% vs 24.6% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 66% vs 5.8% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 70.6% vs 28.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 75.4% vs 30.8% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 68.1% vs 20% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 56.5% vs 12.3% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 62.7% vs 47.1% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 47.1% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 43.1% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 56.3% vs 33.3% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 50% vs 37.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 51.3% vs 24.6% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 33.8% vs 15.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 80.8% vs 21.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 63.9% vs 25.4% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 52.5% vs 27.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 76.9% vs 10.7% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 50.8% vs 15.3% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 31.1% vs 15.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 38.5% vs 3.6% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 68.4% vs 47.1% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 65.3% vs 47.1% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 32.4% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 61.3% vs 47.1% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 35.3% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 62.7% vs 43.1% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 87% vs 11.5% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 71.9% vs 27.1% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 64% vs 33.3% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 66.1% vs 28.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 66.7% vs 25.4% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 56% vs 37.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 77.8% vs 9.6% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 63.2% vs 27.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 54.7% vs 24.6% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 30.8% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 53.7% vs 5.8% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 38.6% vs 15.3% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 15.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 71.0% vs 20% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 43.5% vs 12.3% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 58.8% vs 47.1% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 65.5% vs 47.1% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 64.7% vs 32.4% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 67.3% vs 47.1% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 58.8% vs 35.3% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 60% vs 43.1% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 37.3% vs 23.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 62.3% vs 11.5% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 47.1% vs 27.1% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 66.7% vs 21.4% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.4% vs 33.3% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 47.1% vs 25.4% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 54.4% vs 37.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 47.2% vs 9.6% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 37.3% vs 27.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 55.6% vs 10.7% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 45.6% vs 24.6% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 34% vs 5.8% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 31.4% vs 15.3% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 40.7% vs 10.7% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 36.8% vs 15.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 14.8% vs 3.6% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 35.1% vs 47.1% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 45.9% vs 32.4% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 51.4% vs 35.3% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 63.3% vs 43.1% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 35.2% vs 23.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 37.7% vs 11.5% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 37.0% vs 27.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 67.9% vs 21.4% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 50% vs 33.3% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 38.9% vs 25.4% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 44.3% vs 37.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 35.8% vs 9.6% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 22.2% vs 27.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 37.1% vs 24.6% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 5.8% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 16.7% vs 15.3% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 82.6% vs 65.2% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 76% vs 76.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 32.1% vs 10.7% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 21.4% vs 15.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 28.6% vs 3.6% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 60% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 71% vs 66.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 70% vs 68% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.9% vs 66.8% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.7% vs 67.6% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.4% vs 64.6% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.3% vs 63.6% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.6% vs 65.4% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 57.2% vs 56% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.7% vs 63.5% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 66% vs 62.9% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.1% vs 64.2% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.3% vs 63.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.3% vs 61.1% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 61.6% vs 61.1% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.2% vs 60.9% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 53.6% vs 54.4% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 44% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.8% vs 35.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 29.8% vs 27.6% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 20.8% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 16.7% vs 16% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.8% vs 6.1% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.8% vs 2.5% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.7% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.1% vs 66.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 69% vs 68% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.9% vs 66.8% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 69.5% vs 67.6% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 66.9% vs 64.6% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 63.6% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 65.5% vs 65.4% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 59.5% vs 56% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 63.3% vs 63.5% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 63% vs 62.9% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 61.7% vs 64.2% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 61% vs 63.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 60.5% vs 61.1% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 57.9% vs 61.1% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 58.2% vs 60.9% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 49.3% vs 54.4% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.3% vs 44% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 33.3% vs 35.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.2% vs 27.6% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 20.8% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 16.3% vs 16% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.4% vs 11.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 6.9% vs 6.1% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.5% vs 2.5% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 0.7% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
ACR5064.2% vs 66%−1.8 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 57.9% vs 33.3% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181
32.7% vs 16%+16.7 vs placebo5 mg · wk 52 · n 309NCT00847613
275 other results
  • 32.7% vs 20% 5 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 33.8% vs 12.7% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 36.7% vs 12.3% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 32.4% vs 8.4% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 28.0% vs 8.3% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 31.1% vs 12.5% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 9.6% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 34.2% vs 6.6% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 28.8% vs 7.8% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 26.5% vs 8.4% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 26.1% vs 5.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 23.1% vs 4.5% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 17.4% vs 4.2% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 11.6% vs 1.3% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 14.9% vs 4.7% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 16.8% vs 1.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 12.9% vs 6.1% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 5.8% vs 4.2% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 5.8% vs 1.3% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 7.7% vs 1.6% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 41.1% vs 16% 10 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 44.0% vs 20% 10 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 36.6% vs 12.7% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 34.7% vs 12.3% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 43.7% vs 8.4% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 33.3% vs 8.3% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 36.8% vs 12.5% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 34.0% vs 9.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 27.6% vs 6.6% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 36.3% vs 7.8% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 27.8% vs 8.4% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 33.9% vs 5.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 29.8% vs 4.5% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 24.0% vs 4.2% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 18.1% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 16.3% vs 4.7% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 18.4% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 17.3% vs 6.1% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 12.9% vs 4.2% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 8.1% vs 1.3% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 5.5% vs 1.6% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 36.7% vs 33.7% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 33.7% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 29.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 35.3% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 50.7% vs 33.1% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 46.6% vs 26.6% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 48.0% vs 30.4% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 40.1% vs 20.1% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 49.0% vs 30.4% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 32.6% vs 11.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 18.0% vs 3.8% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 28.3% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 33.7% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 55.6% vs 33.7% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 37.2% vs 29.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 56.9% vs 35.3% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 54.3% vs 33.1% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 56.4% vs 26.6% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 51.8% vs 30.4% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 50% vs 20.1% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 30.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 40.1% vs 11.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 28.0% vs 3.8% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 28.3% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 36.7% vs 17.6% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 39.4% vs 31.4% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 32.7% vs 17.6% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 31.4% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 20.6% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 21.6% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 46.2% vs 7.7% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 38.8% vs 10.2% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 81.5% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 36.6% vs 17.4% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 6.8% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 44.2% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 24.5% vs 8.5% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 70.4% vs 7.1% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 17.9% vs 13.3% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 14.3% vs 6.8% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 31.0% vs 8.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 28.8% vs 1.9% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 10.2% vs 5.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 29.6% vs 3.6% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 2.9% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 11.5% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 25.9% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.6% vs 2.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 3.1% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 6.6% vs 3.1% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 45.9% vs 17.6% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 39.2% vs 31.4% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 17.6% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 40.5% vs 31.4% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 20.6% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 36.5% vs 21.6% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 69.8% vs 7.7% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 45.9% vs 10.2% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 50.8% vs 6.8% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 62.3% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 29.5% vs 8.5% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 36.1% vs 6.8% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 54.7% vs 1.9% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 31.1% vs 5.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 32.1% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 18.0% vs 1.7% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 25% vs 2.9% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 15% vs 2.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 57.7% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 50% vs 7.1% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 27.0% vs 8.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 20.3% vs 2.9% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 26.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 4.0% vs 2.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 45.1% vs 13.3% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 50.7% vs 6.2% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 42.0% vs 6.2% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 29.0% vs 3.1% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 18.8% vs 3.1% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 31.4% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 47.8% vs 31.4% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 41.8% vs 21.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 36.3% vs 17.4% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 32.5% vs 17.4% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 27.5% vs 8.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 7.7% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 54.4% vs 17.6% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 46.7% vs 31.4% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 59.6% vs 17.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 48% vs 31.4% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 56.1% vs 20.6% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 21.6% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 72.2% vs 7.7% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 50.9% vs 10.2% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 44% vs 17.4% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 43.9% vs 6.8% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 66.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 49.1% vs 8.5% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 41.3% vs 17.4% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 30.4% vs 13.3% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 42.1% vs 6.8% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 8.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 53.6% vs 6.2% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 1.9% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 40.4% vs 5.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 26.7% vs 2.9% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 42.0% vs 6.2% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 22.2% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 17.5% vs 1.7% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 17.3% vs 2.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 23.2% vs 3.1% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 8.7% vs 3.1% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 44.1% vs 17.6% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 34.5% vs 31.4% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 44.1% vs 17.6% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 45.5% vs 31.4% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 38.2% vs 20.6% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 43.6% vs 21.6% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 26.4% vs 7.7% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 25.5% vs 10.2% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 44.4% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 29.4% vs 17.4% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 6.8% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 37.7% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 21.6% vs 8.5% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 29.6% vs 7.1% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 15.7% vs 6.8% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 29.4% vs 8.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 22.6% vs 1.9% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 13.7% vs 5.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 22.2% vs 3.6% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 16.2% vs 2.9% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 9.4% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 7.8% vs 1.7% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.9% vs 2.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 3.7% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 10.8% vs 17.6% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 44.9% vs 31.4% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 17.6% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 31.4% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 20.6% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 21.6% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 13.5% vs 7.7% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 11.1% vs 10.2% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 32.1% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 22.9% vs 17.4% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 13.0% vs 6.8% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 11.5% vs 1.9% 1 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 13.0% vs 8.5% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 7.1% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 17.1% vs 17.4% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 14.8% vs 6.8% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 10% vs 8.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 9.6% vs 1.9% 1 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 9.3% vs 5.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 10.7% vs 3.6% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 2.9% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 1.9% vs 1.7% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 2.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 67.4% vs 45.7% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 48% vs 42.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 7.1% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 40% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 43.4% vs 39.8% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 39.8% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.8% vs 40.1% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.6% vs 36.7% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.5% vs 42% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.3% vs 31.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.7% vs 41.9% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 27.6% vs 23.2% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.7% vs 40.8% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 41.1% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.2% vs 42% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.2% vs 40.9% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.4% vs 40.8% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.9% vs 38.7% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.7% vs 40.5% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 35.8% vs 35.8% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 29% vs 29.2% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.1% vs 23.8% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.5% vs 18.5% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 13.7% vs 14.4% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 6.9% vs 7.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 3.6% vs 3.8% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.1% vs 1.9% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.2% vs 0.5% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 39.8% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.7% vs 39.8% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 45.9% vs 40.1% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.2% vs 36.7% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.2% vs 42% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.5% vs 31.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.8% vs 41.9% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 31% vs 23.2% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.3% vs 40.8% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.3% vs 41.1% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.8% vs 42% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 42% vs 40.9% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.9% vs 40.8% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.4% vs 38.7% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 39.7% vs 40.5% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 33% vs 35.8% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.4% vs 29.2% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 23.8% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.6% vs 18.5% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 14.4% vs 14.4% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 7.1% vs 7.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 4.7% vs 3.8% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1.4% vs 1.9% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.4% vs 0.5% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
ACR7044.4% vs 37.7%+6.7 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 36.2% vs 14.9% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181
25.4% vs 12.1%vs MTX5 mg BID · wk 24 · n 366NCT01039688
271 other results
  • 37.3% vs 12.1% 10 mg BID · wk 24 · n 391 · Phase 3 · primary NCT01039688
  • 13.2% vs 3.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 19.9% vs 1.9% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 14.6% vs 1.3% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 11.9% vs 3.2% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 15.3% vs 5.8% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 8.4% vs 1.9% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 12.2% vs 1.9% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 10.7% vs 2.6% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 13.6% vs 1.5% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 10.0% vs 3.3% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 9% vs 1.3% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 5.0% vs 1.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 3.5% vs 0% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 2.6% vs 0.9% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.9% vs 0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 7.6% vs 0% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 2.1% vs 0% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 0.3% vs 0% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 16.2% vs 3.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 21.9% vs 1.9% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 22.3% vs 1.3% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 18.1% vs 3.2% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 20.3% vs 5.8% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 14.2% vs 1.9% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 14.8% vs 1.9% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 17.1% vs 2.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 10.5% vs 1.5% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 19.0% vs 3.3% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 10.4% vs 1.3% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 9.1% vs 1.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 7.1% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 4.1% vs 0.9% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.6% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 6.8% vs 0% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 4.6% vs 0% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 2.3% vs 0% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 23.0% vs 16.6% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 28.7% vs 15.4% 5 mg BID · wk 52 · n 366 · Phase 3 · secondary NCT01039688
  • 18.4% vs 11.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 29.2% vs 13.2% 5 mg BID · wk 39 · n 366 · Phase 3 · secondary NCT01039688
  • 30.1% vs 17.0% 5 mg BID · wk 65 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 15.9% 5 mg BID · wk 78 · n 366 · Phase 3 · secondary NCT01039688
  • 19.9% vs 5.5% 5 mg BID · wk 13 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 17.6% 5 mg BID · wk 91 · n 366 · Phase 3 · secondary NCT01039688
  • 16.2% vs 3.3% 5 mg BID · wk 8.67 · n 366 · Phase 3 · secondary NCT01039688
  • 5.2% vs 0.6% 5 mg BID · wk 4.33 · n 366 · Phase 3 · secondary NCT01039688
  • 34.1% vs 15.4% 5 mg BID · wk 104 · n 366 · Phase 3 · secondary NCT01039688
  • 23.5% vs 16.6% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 15.4% 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • 21.9% vs 11.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 13.2% 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • 37.9% vs 17.0% 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • 36.6% vs 15.9% 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • 26.6% vs 5.5% 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • 36.8% vs 17.6% 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • 23.0% vs 3.3% 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • 9.2% vs 0.6% 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • 37.6% vs 15.4% 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • 22.4% vs 11.8% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 21.1% vs 9.8% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 18.4% vs 8.8% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 23.9% vs 13.7% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 20.4% vs 0% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 18.3% vs 9.8% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 26.9% vs 1.9% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 14.3% vs 3.4% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 18.3% vs 5.8% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 16.3% vs 1.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 25% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 5.8% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 8.9% vs 8.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 4.1% vs 1.7% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 16.9% vs 4.3% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 13.1% vs 3.1% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 17.3% vs 0% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 1.7% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 14.8% vs 0% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 0% vs 1.4% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 1.5% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 1.9% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 11.1% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 4.9% vs 1.5% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 1.6% vs 0% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 37.7% vs 11.8% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 31.1% vs 8.8% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 24.3% vs 13.7% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.5% vs 0% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 49.1% vs 1.9% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 24.6% vs 3.4% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 12.2% vs 5.8% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 37.7% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 16.2% vs 5.8% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 9.5% vs 4.3% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 26.4% vs 0% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 11.5% vs 1.7% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 9.4% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 3.3% vs 0% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 27.4% vs 8.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 27.5% vs 3.1% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 21.7% vs 1.5% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 10.1% vs 1.5% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 28.4% vs 9.8% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 28.4% vs 13.7% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 22.4% vs 9.8% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 23.8% vs 5.8% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 17.5% vs 5.8% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 4.3% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 1.4% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 2.5% vs 0% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 26.2% vs 1.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 18.0% vs 1.7% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 26.9% vs 3.6% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 19.7% vs 1.7% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 7.7% vs 0% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 14.9% vs 1.4% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 33.3% vs 11.8% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 9.8% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 31.6% vs 8.8% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 28% vs 13.7% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 33.3% vs 0% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 9.8% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 51.9% vs 1.9% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 26.3% vs 3.4% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 5.8% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 21.1% vs 1.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 40.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 24.6% vs 1.7% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 5.8% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 14.3% vs 8.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 17.5% vs 1.7% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 4.3% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 21.7% vs 3.1% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 16.7% vs 0% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 8.8% vs 1.7% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 13.3% vs 1.4% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 17.4% vs 1.5% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 7.4% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 6.7% vs 0% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 4.3% vs 1.5% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 23.5% vs 11.8% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 23.6% vs 9.8% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 8.8% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 29.1% vs 13.7% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 26.5% vs 0% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 21.8% vs 9.8% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 13.2% vs 1.9% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 11.8% vs 3.4% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.6% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 20.6% vs 5.8% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 7.8% vs 1.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 3.9% vs 1.7% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 3.6% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 14.7% vs 5.8% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 2.0% vs 1.7% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 4.3% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 3.8% vs 0% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 5.9% vs 1.7% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 7.3% vs 1.4% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 3.7% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.5% vs 0% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 8.1% vs 11.8% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 9.8% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 8.8% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 20.4% vs 13.7% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 0% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 16.3% vs 9.8% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 7.5% vs 1.9% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 5.6% vs 3.4% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 3.6% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 5.8% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 5.7% vs 1.9% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 9.3% vs 1.7% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 3.6% vs 3.6% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 8.6% vs 5.8% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 1.4% vs 4.3% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 0% vs 1.7% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 0% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 1.9% vs 0% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 34.8% vs 30.4% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 20% vs 19.1% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 3.6% vs 0% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 2.9% vs 1.4% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 6.7% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 23.2% vs 19.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.5% vs 20.1% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.7% vs 21% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.4% vs 16.1% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.6% vs 22.4% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.4% vs 13.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 22.2% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 7.8% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 24% vs 22.6% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.7% vs 23.6% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.4% vs 24.7% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.5% vs 24.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 24.2% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.5% vs 23.3% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.8% vs 23.6% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 21.5% vs 20.5% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.6% vs 16.4% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 14.8% vs 13.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.9% vs 11% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 8.8% vs 8.1% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.4% vs 6.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 4% vs 4.4% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.7% vs 2.4% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.5% vs 1% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.1% vs 0.3% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.6% vs 19.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.2% vs 20.1% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 21% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 22.7% vs 16.1% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.2% vs 22.4% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.4% vs 13.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.4% vs 22.2% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.3% vs 7.8% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.5% vs 22.6% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 23.6% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.3% vs 24.7% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.9% vs 24.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.6% vs 24.2% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 24.8% vs 23.3% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.5% vs 23.6% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 20.5% vs 20.5% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 15.7% vs 16.4% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.4% vs 13.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 8.7% vs 8.1% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 5.7% vs 6.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 3.9% vs 4.4% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.6% vs 2.4% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 1% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.3% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
DAS28-CRP remission54.5% vs 50.8%+3.7 vs placebo200 mg · wk 52 · n 475NCT02889796
35 other results
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 48.4% vs 16.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
23.0% vs 5.2%+17.8 vs placebo5 mg · wk 26 · n 309NCT00847613
174 other results
  • 20.4% vs 5.2% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 11.3% vs 2.0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 36.4% vs 5.2% 10 mg · wk 26 · n 308 · Phase 3 · secondary NCT00847613
  • 26.9% vs 5.2% 10 mg · wk 13 · n 308 · Phase 3 · secondary NCT00847613
  • 9.1% vs 2.0% 10 mg · wk 4.33 · n 308 · Phase 3 · secondary NCT00847613
  • 36.5% vs 20.6% 5 mg BID · wk 52 · n 367 · Phase 3 · secondary NCT01039688
  • 36.2% vs 17.4% 5 mg BID · wk 39 · n 367 · Phase 3 · secondary NCT01039688
  • 37.6% vs 19.6% 5 mg BID · wk 65 · n 367 · Phase 3 · secondary NCT01039688
  • 31.3% vs 15.2% 5 mg BID · wk 26 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 19.0% 5 mg BID · wk 78 · n 367 · Phase 3 · secondary NCT01039688
  • 25.9% vs 9.8% 5 mg BID · wk 13 · n 367 · Phase 3 · secondary NCT01039688
  • 37.1% vs 17.4% 5 mg BID · wk 91 · n 367 · Phase 3 · secondary NCT01039688
  • 20.4% vs 5.4% 5 mg BID · wk 8.67 · n 367 · Phase 3 · secondary NCT01039688
  • 7.4% vs 2.7% 5 mg BID · wk 4.33 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 18.5% 5 mg BID · wk 104 · n 367 · Phase 3 · secondary NCT01039688
  • 49.5% vs 20.6% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 45.7% vs 17.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 19.6% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 47.2% vs 15.2% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 19.0% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 37.8% vs 9.8% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 17.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 28.7% vs 5.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 14.1% vs 2.7% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 43.9% vs 18.5% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 65.9% vs 30% 5 mg · wk 24 · n 40 · Phase 2 · secondary NCT00550446
  • 22% vs 15% 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • 41.5% vs 19.4% 5 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 68.9% vs 16.7% 5 mg · wk 20 · n 40 · Phase 2 · secondary NCT00550446
  • 20% vs 5.6% 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • 35.1% vs 13.9% 5 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 69.6% vs 35% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT00550446
  • 28.3% vs 15% 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • 24.1% vs 8.1% 5 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 6.7% 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT00550446
  • 24.4% vs 6.7% 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • 16.7% vs 6.7% 5 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 65.8% vs 3.3% 5 mg · wk 10 · n 40 · Phase 2 · secondary NCT00550446
  • 21.7% vs 4.3% 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • 66.7% vs 9.7% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT00550446
  • 14.9% vs 4.4% 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • 19.4% vs 6.9% 5 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 56.4% vs 5.9% 5 mg · wk 6 · n 40 · Phase 2 · secondary NCT00550446
  • 8.9% vs 1.9% 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • 13.6% vs 3.5% 5 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT00550446
  • 4.4% vs 1.9% 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • 8.1% vs 3.3% 5 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 62.5% vs 2.7% 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT00550446
  • 4.2% vs 0% 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 5 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 72.7% vs 30% 10 mg · wk 24 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT00550446
  • 36.5% vs 19.4% 10 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 88.7% vs 16.7% 10 mg · wk 20 · n 45 · Phase 2 · secondary NCT00550446
  • 43.4% vs 5.6% 10 mg · wk 20 · n 60 · Phase 2 · secondary NCT00550446
  • 37.1% vs 13.9% 10 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 78.2% vs 35% 10 mg · wk 16 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 16 · n 60 · Phase 2 · secondary NCT00550446
  • 30.2% vs 8.1% 10 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 75.6% vs 6.7% 10 mg · wk 12 · n 45 · Phase 2 · secondary NCT00550446
  • 33.3% vs 6.7% 10 mg · wk 12 · n 60 · Phase 2 · secondary NCT00550446
  • 32.3% vs 6.7% 10 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 90.7% vs 3.3% 10 mg · wk 10 · n 45 · Phase 2 · secondary NCT00550446
  • 31.6% vs 4.3% 10 mg · wk 10 · n 60 · Phase 2 · secondary NCT00550446
  • 78.6% vs 9.7% 10 mg · wk 8 · n 45 · Phase 2 · secondary NCT00550446
  • 21.4% vs 4.4% 10 mg · wk 8 · n 60 · Phase 2 · secondary NCT00550446
  • 21.3% vs 6.9% 10 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 79.5% vs 5.9% 10 mg · wk 6 · n 45 · Phase 2 · secondary NCT00550446
  • 24.1% vs 1.9% 10 mg · wk 6 · n 60 · Phase 2 · secondary NCT00550446
  • 24.2% vs 3.5% 10 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 83.7% vs 5.7% 10 mg · wk 4 · n 45 · Phase 2 · secondary NCT00550446
  • 17.5% vs 1.9% 10 mg · wk 4 · n 60 · Phase 2 · secondary NCT00550446
  • 19.1% vs 3.3% 10 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 71.1% vs 2.7% 10 mg · wk 2 · n 45 · Phase 2 · secondary NCT00550446
  • 5% vs 0% 10 mg · wk 2 · n 60 · Phase 2 · secondary NCT00550446
  • 4.4% vs 3.3% 10 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 32.7% vs 19.4% 20 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 30.9% vs 13.9% 20 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.1% vs 8.1% 20 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 24.6% vs 6.7% 20 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 20.9% vs 6.9% 20 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 10.1% vs 3.5% 20 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 10% vs 3.3% 20 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 4.0% vs 3.3% 20 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 84.6% vs 30% 15 mg · wk 24 · n 39 · Phase 2 · secondary NCT00550446
  • 50% vs 15% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 39.3% vs 19.4% 15 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 76.9% vs 16.7% 15 mg · wk 20 · n 39 · Phase 2 · secondary NCT00550446
  • 42.3% vs 5.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 38.6% vs 13.9% 15 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 82.4% vs 35% 15 mg · wk 16 · n 39 · Phase 2 · secondary NCT00550446
  • 43.1% vs 15% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 37.9% vs 8.1% 15 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 68.6% vs 6.7% 15 mg · wk 12 · n 39 · Phase 2 · secondary NCT00550446
  • 40.4% vs 6.7% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 37.1% vs 6.7% 15 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 79.4% vs 3.3% 15 mg · wk 10 · n 39 · Phase 2 · secondary NCT00550446
  • 38.5% vs 4.3% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 75% vs 9.7% 15 mg · wk 8 · n 39 · Phase 2 · secondary NCT00550446
  • 41.5% vs 4.4% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 23.9% vs 6.9% 15 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 67.6% vs 5.9% 15 mg · wk 6 · n 39 · Phase 2 · secondary NCT00550446
  • 32.7% vs 1.9% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 22.7% vs 3.5% 15 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 15 mg · wk 4 · n 39 · Phase 2 · secondary NCT00550446
  • 15.1% vs 1.9% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 16.9% vs 3.3% 15 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 66.7% vs 2.7% 15 mg · wk 2 · n 39 · Phase 2 · secondary NCT00550446
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 13.2% vs 3.3% 15 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 46.4% vs 30% 3 mg · wk 24 · n 33 · Phase 2 · secondary NCT00550446
  • 39.3% vs 15% 3 mg · wk 24 · n 50 · Phase 2 · secondary NCT00550446
  • 35.7% vs 19.4% 3 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 58.6% vs 16.7% 3 mg · wk 20 · n 33 · Phase 2 · secondary NCT00550446
  • 20.7% vs 5.6% 3 mg · wk 20 · n 50 · Phase 2 · secondary NCT00550446
  • 43.2% vs 13.9% 3 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 35% 3 mg · wk 16 · n 33 · Phase 2 · secondary NCT00550446
  • 30% vs 15% 3 mg · wk 16 · n 50 · Phase 2 · secondary NCT00550446
  • 41.9% vs 8.1% 3 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 42.9% vs 6.7% 3 mg · wk 12 · n 33 · Phase 2 · secondary NCT00550446
  • 8.9% vs 6.7% 3 mg · wk 12 · n 50 · Phase 2 · secondary NCT00550446
  • 30.9% vs 6.7% 3 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 3.3% 3 mg · wk 10 · n 33 · Phase 2 · secondary NCT00550446
  • 8.5% vs 4.3% 3 mg · wk 10 · n 50 · Phase 2 · secondary NCT00550446
  • 46.7% vs 9.7% 3 mg · wk 8 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 4.4% 3 mg · wk 8 · n 50 · Phase 2 · secondary NCT00550446
  • 22.0% vs 6.9% 3 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 43.3% vs 5.9% 3 mg · wk 6 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 1.9% 3 mg · wk 6 · n 50 · Phase 2 · secondary NCT00550446
  • 19.7% vs 3.5% 3 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 5.7% 3 mg · wk 4 · n 33 · Phase 2 · secondary NCT00550446
  • 6.5% vs 1.9% 3 mg · wk 4 · n 50 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.3% 3 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 2.7% 3 mg · wk 2 · n 33 · Phase 2 · secondary NCT00550446
  • 4% vs 0% 3 mg · wk 2 · n 50 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.3% 3 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 30% 1 mg · wk 24 · n 43 · Phase 2 · secondary NCT00550446
  • 16.7% vs 15% 1 mg · wk 24 · n 53 · Phase 2 · secondary NCT00550446
  • 23.1% vs 19.4% 1 mg · wk 24 · n 64 · Phase 2 · secondary NCT00413660
  • 46.2% vs 16.7% 1 mg · wk 20 · n 43 · Phase 2 · secondary NCT00550446
  • 19.2% vs 5.6% 1 mg · wk 20 · n 53 · Phase 2 · secondary NCT00550446
  • 20.5% vs 13.9% 1 mg · wk 20 · n 64 · Phase 2 · secondary NCT00413660
  • 48.1% vs 35% 1 mg · wk 16 · n 43 · Phase 2 · secondary NCT00550446
  • 22.2% vs 15% 1 mg · wk 16 · n 53 · Phase 2 · secondary NCT00550446
  • 14.3% vs 8.1% 1 mg · wk 16 · n 64 · Phase 2 · secondary NCT00413660
  • 22.2% vs 6.7% 1 mg · wk 12 · n 43 · Phase 2 · secondary NCT00550446
  • 9.3% vs 6.7% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00550446
  • 6.6% vs 6.7% 1 mg · wk 12 · n 64 · Phase 2 · secondary NCT00413660
  • 26.3% vs 3.3% 1 mg · wk 10 · n 43 · Phase 2 · secondary NCT00550446
  • 10.9% vs 4.3% 1 mg · wk 10 · n 53 · Phase 2 · secondary NCT00550446
  • 25.6% vs 9.7% 1 mg · wk 8 · n 43 · Phase 2 · secondary NCT00550446
  • 2.1% vs 4.4% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00550446
  • 7.9% vs 6.9% 1 mg · wk 8 · n 64 · Phase 2 · secondary NCT00413660
  • 20.5% vs 5.9% 1 mg · wk 6 · n 43 · Phase 2 · secondary NCT00550446
  • 8.5% vs 1.9% 1 mg · wk 6 · n 53 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.5% 1 mg · wk 6 · n 64 · Phase 2 · secondary NCT00413660
  • 30% vs 5.7% 1 mg · wk 4 · n 43 · Phase 2 · secondary NCT00550446
  • 6% vs 1.9% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00550446
  • 4.6% vs 3.3% 1 mg · wk 4 · n 64 · Phase 2 · secondary NCT00413660
  • 25.6% vs 2.7% 1 mg · wk 2 · n 43 · Phase 2 · secondary NCT00550446
  • 1.9% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 1 mg · wk 2 · n 64 · Phase 2 · secondary NCT00413660
  • 16.7% vs 19.4% 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • 0% vs 13.9% 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • 11.1% vs 8.1% 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • 15.4% vs 19.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 15.4% vs 13.9% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 23.1% vs 8.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 25% vs 19.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 28.6% vs 13.9% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 9.5% vs 8.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 24% vs 22.4% 11mg MR · wk 24 · n 100 · Phase 2 · secondary NCT04413617
  • 40.8% vs 22.4% 400mg MR + 11mg MR · wk 24 · n 103 · Phase 2 · secondary NCT04413617
HAQ-DI, change-0.9 vs -0.7−0.2 vs placebo200 mg · wk 52 · n 475NCT02889796
36 other results
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181
-0.5 vs -0.2−0.3 vs placebo5 mg · wk 13 · n 240NCT00814307
233 other results
  • -0.5 vs -0.2 5 mg · wk 13 · n 311 · Phase 3 · primary NCT00856544
  • -0.5 vs -0.2 5 mg twice daily · wk 13 · n 201 · Phase 3 · primary NCT00853385
  • -0.3 vs -0.1 5 mg · wk 13 · n 315 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 5 mg · wk 13 · n 132 · Phase 3 · primary NCT00960440
  • -0.5 vs -0.2 10 mg · wk 13 · n 241 · Phase 3 · primary NCT00814307
  • -0.5 vs -0.2 10 mg · wk 13 · n 315 · Phase 3 · primary NCT00856544
  • -0.6 vs -0.2 10 mg twice daily · wk 13 · n 199 · Phase 3 · primary NCT00853385
  • -0.4 vs -0.1 10 mg · wk 13 · n 309 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 10 mg · wk 13 · n 134 · Phase 3 · primary NCT00960440
  • -0.9 vs -0.7 5 mg BID · wk 52 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.7 5 mg BID · wk 39 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 65 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.6 5 mg BID · wk 26 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 78 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 5 mg BID · wk 13 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 91 · n 365 · Phase 3 · secondary NCT01039688
  • -0.7 vs -0.3 5 mg BID · wk 8.67 · n 365 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.2 5 mg BID · wk 4.33 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 104 · n 365 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.6 10 mg BID · wk 26 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • -1 vs -0.7 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.3 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • -0.6 vs -0.2 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.4 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.3 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 5 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs 0.2 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 5 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.2 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.2 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.0 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 5 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 5 mg BID · wk 8 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.2 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 5 mg BID · wk 6 · n 59 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.0 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 5 mg BID · wk 4 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs 0.1 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • -0.2 vs -0.0 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.0 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 5 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 5 mg BID · wk 2 · n 59 · Phase 2 · secondary NCT00147498
  • -0.1 vs 0 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg BID · wk 1 · n 59 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.4 10 mg · wk 24 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 20 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 16 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.3 10 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.2 10 mg · wk 12 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.2 10 mg · wk 10 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.5 vs -0.2 10 mg · wk 8 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.2 10 mg · wk 6 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 10 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.1 10 mg · wk 4 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.1 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 10 mg · wk 2 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 20 mg · wk 4 · n 79 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.1 20 mg · wk 2 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 10 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.0 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 10 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 30 mg BID · wk 8 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 30 mg BID · wk 6 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.1 30 mg BID · wk 4 · n 64 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.1 30 mg BID · wk 2 · n 64 · Phase 2 · secondary NCT00147498
  • -0.4 vs -0.1 30 mg BID · wk 1 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.4 20 mg · wk 24 · n 79 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.4 20 mg · wk 20 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 20 mg · wk 16 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 20 mg · wk 8 · n 79 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 20 mg · wk 6 · n 79 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • -0.8 vs -0.4 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 15 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • -0.8 vs -0.2 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 15 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.8 vs -0.2 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • -0.7 vs -0.2 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 15 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 15 mg BID · wk 8 · n 68 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 15 mg BID · wk 6 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs 0.0 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.1 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 15 mg BID · wk 4 · n 68 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.1 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.0 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 15 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 15 mg BID · wk 2 · n 68 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.1 15 mg BID · wk 1 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs -0.4 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 3 mg · wk 24 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 3 mg · wk 20 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.3 3 mg · wk 16 · n 66 · Phase 2 · secondary NCT00413660
  • -0.4 vs 0.2 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 3 mg · wk 12 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.2 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs 0.0 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 8 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 6 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0.0 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 4 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.0 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 3 mg · wk 2 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.6 vs -0.4 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 1 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.2 vs 0.2 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 1 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs 0.2 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.0 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 1 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 1 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.0 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.1 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 1 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.0 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • -0.1 vs -0.0 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • -0.1 vs -0.1 1 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • 0.1 vs -0.1 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • -0.4 vs -0.0 wk 6 · n 93 · Phase 1 · secondary NCT01484561
  • -0.5 vs -0.4 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.4 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.4 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.3 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.3 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.5 5 mg BID · wk 52 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 39 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 65 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 26 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 78 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 5 mg BID · wk 13 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 91 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.4 vs -0.4 5 mg BID · wk 8.67 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 104 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 117 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 130 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 143 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 156 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 169 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 182 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 195 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 208 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 221 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 234 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 247 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 260 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 273 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 52 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 39 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 65 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 26 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 78 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 13 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 91 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 8.67 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 104 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 117 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 130 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 143 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 156 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 169 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 182 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 195 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 208 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 221 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 234 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 247 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 260 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 273 · n 1390 · Phase 4 · secondary NCT02092467
Modified Sharp score, change0.2 vs 0.9−0.7 vs placebo200 mg · wk 52 · n 468NCT02889796
9 other results
  • 0.1 vs 0.4 200 mg · wk 24 · n 467 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
0.1 vs 0.5−0.3 vs placebo5 mg · wk 26 · n 286NCT00847613
7 other results
  • 0.1 vs 0.5 10 mg · wk 26 · n 295 · Phase 3 · primary NCT00847613
  • 0.2 vs 0.7 5 mg BID · wk 24 · n 346 · Phase 3 · primary NCT01039688
  • 0.1 vs 0.7 10 mg BID · wk 24 · n 370 · Phase 3 · primary NCT01039688
  • 0.4 vs 1.2 5 mg BID · wk 52 · n 346 · Phase 3 · secondary NCT01039688
  • 0.6 vs 2.1 5 mg BID · wk 104 · n 346 · Phase 3 · secondary NCT01039688
  • 0.2 vs 1.2 10 mg BID · wk 52 · n 371 · Phase 3 · secondary NCT01039688
  • 0.3 vs 2.1 10 mg BID · wk 104 · n 371 · Phase 3 · secondary NCT01039688

ACR20

filgotinib
76.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181
tofacitinib
52.7% vs 31.2%+21.5 vs placebo5 mg · wk 24 · n 311NCT00856544
273 other results
  • 51.5% vs 28.3% 5 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 51.5% vs 25.3% 5 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 59.8% vs 26.7% 5 mg · wk 12 · n 241 · Phase 3 · primary NCT00814307
  • 41.7% vs 24.4% 5 mg · wk 12 · n 132 · Phase 3 · primary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00856544
  • 52.5% vs 28.3% 10 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 61.8% vs 25.3% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 65.7% vs 26.7% 10 mg · wk 12 · n 242 · Phase 3 · primary NCT00814307
  • 48.1% vs 24.4% 10 mg · wk 12 · n 133 · Phase 3 · primary NCT00960440
  • 52.7% vs 31.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 50.8% vs 25.5% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 56.3% vs 27.4% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 60.7% vs 26.4% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 56.3% vs 27.3% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 56.9% vs 25.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 54.0% vs 26.1% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 46.5% vs 21.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 38.6% vs 22.9% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 41.2% vs 16.0% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 41.4% vs 16.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 42.4% vs 27.5% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 29.6% vs 11.8% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 10.9% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 27.7% vs 16.7% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 57.9% vs 25.5% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 64.7% vs 27.4% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 58.7% vs 26.4% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 66.3% vs 27.3% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 60.7% vs 25.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 64.4% vs 26.1% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 52.1% vs 21.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 48.5% vs 22.9% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 45.9% vs 16.0% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 52.1% vs 16.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 44.4% vs 27.5% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 39.2% vs 11.8% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 32.3% vs 10.9% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 32.8% vs 16.7% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 49.5% vs 49.3% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 67.8% vs 51.1% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 47.2% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 72.1% vs 55.4% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 68.8% vs 47.3% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 71.3% vs 50.5% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 46.7% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 69.9% vs 51.6% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 65.0% vs 45.1% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 63.6% vs 42.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 21.2% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 71.6% vs 51.1% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 47.2% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 73.6% vs 55.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 66.2% vs 47.3% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 76.1% vs 50.5% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 66.0% vs 46.7% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 77.9% vs 51.6% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 62.2% vs 45.1% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 71.6% vs 42.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 58.3% vs 21.2% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 73.1% vs 15.4% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT00687193
  • 61.2% vs 23.7% 5 mg · wk 12 · n 49 · Phase 2 · primary NCT00550446
  • 96.3% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 56.3% vs 36.2% 5 mg · wk 12 · n 71 · Phase 2 · primary NCT00413660
  • 70.5% vs 29.2% 5 mg BID · wk 6 · n 61 · Phase 2 · primary NCT00147498
  • 84.9% vs 15.4% 10 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 72.1% vs 23.7% 10 mg · wk 12 · n 61 · Phase 2 · primary NCT00550446
  • 80.8% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · primary NCT00603512
  • 58.1% vs 36.2% 10 mg · wk 12 · n 74 · Phase 2 · primary NCT00413660
  • 76.8% vs 29.2% 30 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 56.3% vs 36.2% 20 mg · wk 12 · n 80 · Phase 2 · primary NCT00413660
  • 90.7% vs 15.4% 15 mg · wk 12 · n 54 · Phase 2 · primary NCT00687193
  • 71.9% vs 23.7% 15 mg · wk 12 · n 57 · Phase 2 · primary NCT00550446
  • 56% vs 36.2% 15 mg · wk 12 · n 75 · Phase 2 · primary NCT00413660
  • 81.2% vs 29.2% 15 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 67.9% vs 15.4% 3 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 45.1% vs 23.7% 3 mg · wk 12 · n 51 · Phase 2 · primary NCT00550446
  • 77.8% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 55.9% vs 36.2% 3 mg · wk 12 · n 68 · Phase 2 · primary NCT00413660
  • 37.7% vs 15.4% 1 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 31.5% vs 23.7% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT00550446
  • 64.3% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · primary NCT00603512
  • 47.1% vs 36.2% 1 mg · wk 12 · n 70 · Phase 2 · primary NCT00413660
  • 57.1% vs 47.1% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 69.4% vs 32.4% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 57.7% vs 47.1% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 67.3% vs 35.3% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 53.5% vs 43.1% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 57.1% vs 23.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 67.3% vs 11.5% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 63.3% vs 27.1% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 96.3% vs 21.4% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.9% vs 33.3% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 50% vs 28.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 63.3% vs 25.4% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 57.8% vs 37.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 61.5% vs 9.6% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 40.8% vs 27.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 88.9% vs 10.7% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 46.5% vs 24.6% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 63.9% vs 30.8% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 34.6% vs 5.8% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 32.6% vs 15.3% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 63.0% vs 10.7% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 31.0% vs 15.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 50.8% vs 20% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 29.6% vs 3.6% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 27.9% vs 12.3% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 73.8% vs 47.1% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 66.2% vs 47.1% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 73.8% vs 32.4% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 62.2% vs 47.1% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 70.5% vs 35.3% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 64.9% vs 43.1% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 86.8% vs 11.5% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 65.6% vs 27.1% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 56.8% vs 33.3% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 55.4% vs 37.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 81.1% vs 9.6% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 46.0% vs 24.6% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 66% vs 5.8% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 70.6% vs 28.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 75.4% vs 30.8% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 68.1% vs 20% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 56.5% vs 12.3% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 62.7% vs 47.1% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 47.1% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 43.1% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 56.3% vs 33.3% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 50% vs 37.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 51.3% vs 24.6% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 33.8% vs 15.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 80.8% vs 21.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 63.9% vs 25.4% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 52.5% vs 27.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 76.9% vs 10.7% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 50.8% vs 15.3% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 31.1% vs 15.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 38.5% vs 3.6% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 68.4% vs 47.1% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 65.3% vs 47.1% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 32.4% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 61.3% vs 47.1% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 35.3% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 62.7% vs 43.1% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 87% vs 11.5% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 71.9% vs 27.1% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 64% vs 33.3% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 66.1% vs 28.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 66.7% vs 25.4% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 56% vs 37.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 77.8% vs 9.6% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 63.2% vs 27.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 54.7% vs 24.6% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 30.8% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 53.7% vs 5.8% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 38.6% vs 15.3% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 15.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 71.0% vs 20% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 43.5% vs 12.3% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 58.8% vs 47.1% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 65.5% vs 47.1% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 64.7% vs 32.4% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 67.3% vs 47.1% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 58.8% vs 35.3% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 60% vs 43.1% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 37.3% vs 23.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 62.3% vs 11.5% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 47.1% vs 27.1% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 66.7% vs 21.4% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.4% vs 33.3% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 47.1% vs 25.4% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 54.4% vs 37.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 47.2% vs 9.6% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 37.3% vs 27.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 55.6% vs 10.7% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 45.6% vs 24.6% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 34% vs 5.8% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 31.4% vs 15.3% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 40.7% vs 10.7% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 36.8% vs 15.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 14.8% vs 3.6% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 35.1% vs 47.1% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 45.9% vs 32.4% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 51.4% vs 35.3% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 63.3% vs 43.1% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 35.2% vs 23.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 37.7% vs 11.5% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 37.0% vs 27.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 67.9% vs 21.4% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 50% vs 33.3% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 38.9% vs 25.4% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 44.3% vs 37.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 35.8% vs 9.6% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 22.2% vs 27.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 37.1% vs 24.6% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 5.8% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 16.7% vs 15.3% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 82.6% vs 65.2% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 76% vs 76.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 32.1% vs 10.7% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 21.4% vs 15.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 28.6% vs 3.6% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 60% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 71% vs 66.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 70% vs 68% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.9% vs 66.8% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.7% vs 67.6% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.4% vs 64.6% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.3% vs 63.6% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.6% vs 65.4% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 57.2% vs 56% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.7% vs 63.5% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 66% vs 62.9% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.1% vs 64.2% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.3% vs 63.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.3% vs 61.1% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 61.6% vs 61.1% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.2% vs 60.9% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 53.6% vs 54.4% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 44% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.8% vs 35.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 29.8% vs 27.6% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 20.8% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 16.7% vs 16% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.8% vs 6.1% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.8% vs 2.5% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.7% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.1% vs 66.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 69% vs 68% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.9% vs 66.8% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 69.5% vs 67.6% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 66.9% vs 64.6% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 63.6% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 65.5% vs 65.4% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 59.5% vs 56% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 63.3% vs 63.5% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 63% vs 62.9% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 61.7% vs 64.2% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 61% vs 63.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 60.5% vs 61.1% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 57.9% vs 61.1% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 58.2% vs 60.9% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 49.3% vs 54.4% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.3% vs 44% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 33.3% vs 35.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.2% vs 27.6% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 20.8% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 16.3% vs 16% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.4% vs 11.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 6.9% vs 6.1% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.5% vs 2.5% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 0.7% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467

ACR50

filgotinib
64.2% vs 66%−1.8 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 57.9% vs 33.3% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181
tofacitinib
32.7% vs 16%+16.7 vs placebo5 mg · wk 52 · n 309NCT00847613
275 other results
  • 32.7% vs 20% 5 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 33.8% vs 12.7% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 36.7% vs 12.3% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 32.4% vs 8.4% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 28.0% vs 8.3% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 31.1% vs 12.5% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 9.6% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 34.2% vs 6.6% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 28.8% vs 7.8% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 26.5% vs 8.4% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 26.1% vs 5.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 23.1% vs 4.5% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 17.4% vs 4.2% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 11.6% vs 1.3% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 14.9% vs 4.7% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 16.8% vs 1.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 12.9% vs 6.1% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 5.8% vs 4.2% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 5.8% vs 1.3% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 7.7% vs 1.6% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 41.1% vs 16% 10 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 44.0% vs 20% 10 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 36.6% vs 12.7% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 34.7% vs 12.3% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 43.7% vs 8.4% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 33.3% vs 8.3% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 36.8% vs 12.5% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 34.0% vs 9.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 27.6% vs 6.6% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 36.3% vs 7.8% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 27.8% vs 8.4% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 33.9% vs 5.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 29.8% vs 4.5% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 24.0% vs 4.2% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 18.1% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 16.3% vs 4.7% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 18.4% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 17.3% vs 6.1% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 12.9% vs 4.2% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 8.1% vs 1.3% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 5.5% vs 1.6% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 36.7% vs 33.7% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 33.7% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 29.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 35.3% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 50.7% vs 33.1% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 46.6% vs 26.6% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 48.0% vs 30.4% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 40.1% vs 20.1% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 49.0% vs 30.4% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 32.6% vs 11.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 18.0% vs 3.8% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 28.3% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 33.7% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 55.6% vs 33.7% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 37.2% vs 29.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 56.9% vs 35.3% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 54.3% vs 33.1% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 56.4% vs 26.6% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 51.8% vs 30.4% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 50% vs 20.1% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 30.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 40.1% vs 11.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 28.0% vs 3.8% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 28.3% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 36.7% vs 17.6% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 39.4% vs 31.4% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 32.7% vs 17.6% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 31.4% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 20.6% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 21.6% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 46.2% vs 7.7% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 38.8% vs 10.2% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 81.5% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 36.6% vs 17.4% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 6.8% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 44.2% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 24.5% vs 8.5% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 70.4% vs 7.1% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 17.9% vs 13.3% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 14.3% vs 6.8% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 31.0% vs 8.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 28.8% vs 1.9% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 10.2% vs 5.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 29.6% vs 3.6% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 2.9% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 11.5% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 25.9% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.6% vs 2.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 3.1% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 6.6% vs 3.1% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 45.9% vs 17.6% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 39.2% vs 31.4% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 17.6% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 40.5% vs 31.4% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 20.6% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 36.5% vs 21.6% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 69.8% vs 7.7% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 45.9% vs 10.2% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 50.8% vs 6.8% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 62.3% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 29.5% vs 8.5% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 36.1% vs 6.8% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 54.7% vs 1.9% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 31.1% vs 5.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 32.1% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 18.0% vs 1.7% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 25% vs 2.9% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 15% vs 2.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 57.7% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 50% vs 7.1% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 27.0% vs 8.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 20.3% vs 2.9% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 26.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 4.0% vs 2.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 45.1% vs 13.3% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 50.7% vs 6.2% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 42.0% vs 6.2% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 29.0% vs 3.1% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 18.8% vs 3.1% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 31.4% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 47.8% vs 31.4% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 41.8% vs 21.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 36.3% vs 17.4% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 32.5% vs 17.4% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 27.5% vs 8.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 7.7% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 54.4% vs 17.6% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 46.7% vs 31.4% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 59.6% vs 17.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 48% vs 31.4% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 56.1% vs 20.6% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 21.6% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 72.2% vs 7.7% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 50.9% vs 10.2% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 44% vs 17.4% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 43.9% vs 6.8% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 66.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 49.1% vs 8.5% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 41.3% vs 17.4% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 30.4% vs 13.3% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 42.1% vs 6.8% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 8.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 53.6% vs 6.2% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 1.9% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 40.4% vs 5.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 26.7% vs 2.9% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 42.0% vs 6.2% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 22.2% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 17.5% vs 1.7% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 17.3% vs 2.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 23.2% vs 3.1% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 8.7% vs 3.1% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 44.1% vs 17.6% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 34.5% vs 31.4% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 44.1% vs 17.6% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 45.5% vs 31.4% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 38.2% vs 20.6% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 43.6% vs 21.6% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 26.4% vs 7.7% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 25.5% vs 10.2% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 44.4% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 29.4% vs 17.4% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 6.8% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 37.7% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 21.6% vs 8.5% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 29.6% vs 7.1% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 15.7% vs 6.8% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 29.4% vs 8.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 22.6% vs 1.9% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 13.7% vs 5.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 22.2% vs 3.6% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 16.2% vs 2.9% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 9.4% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 7.8% vs 1.7% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.9% vs 2.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 3.7% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 10.8% vs 17.6% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 44.9% vs 31.4% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 17.6% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 31.4% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 20.6% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 21.6% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 13.5% vs 7.7% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 11.1% vs 10.2% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 32.1% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 22.9% vs 17.4% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 13.0% vs 6.8% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 11.5% vs 1.9% 1 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 13.0% vs 8.5% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 7.1% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 17.1% vs 17.4% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 14.8% vs 6.8% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 10% vs 8.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 9.6% vs 1.9% 1 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 9.3% vs 5.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 10.7% vs 3.6% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 2.9% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 1.9% vs 1.7% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 2.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 67.4% vs 45.7% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 48% vs 42.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 7.1% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 40% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 43.4% vs 39.8% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 39.8% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.8% vs 40.1% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.6% vs 36.7% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.5% vs 42% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.3% vs 31.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.7% vs 41.9% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 27.6% vs 23.2% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.7% vs 40.8% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 41.1% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.2% vs 42% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.2% vs 40.9% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.4% vs 40.8% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.9% vs 38.7% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.7% vs 40.5% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 35.8% vs 35.8% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 29% vs 29.2% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.1% vs 23.8% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.5% vs 18.5% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 13.7% vs 14.4% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 6.9% vs 7.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 3.6% vs 3.8% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.1% vs 1.9% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.2% vs 0.5% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 39.8% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.7% vs 39.8% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 45.9% vs 40.1% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.2% vs 36.7% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.2% vs 42% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.5% vs 31.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.8% vs 41.9% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 31% vs 23.2% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.3% vs 40.8% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.3% vs 41.1% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.8% vs 42% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 42% vs 40.9% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.9% vs 40.8% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.4% vs 38.7% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 39.7% vs 40.5% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 33% vs 35.8% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.4% vs 29.2% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 23.8% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.6% vs 18.5% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 14.4% vs 14.4% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 7.1% vs 7.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 4.7% vs 3.8% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1.4% vs 1.9% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.4% vs 0.5% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467

ACR70

filgotinib
44.4% vs 37.7%+6.7 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 36.2% vs 14.9% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181
tofacitinib
25.4% vs 12.1%vs MTX5 mg BID · wk 24 · n 366NCT01039688
271 other results
  • 37.3% vs 12.1% 10 mg BID · wk 24 · n 391 · Phase 3 · primary NCT01039688
  • 13.2% vs 3.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 19.9% vs 1.9% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 14.6% vs 1.3% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 11.9% vs 3.2% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 15.3% vs 5.8% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 8.4% vs 1.9% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 12.2% vs 1.9% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 10.7% vs 2.6% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 13.6% vs 1.5% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 10.0% vs 3.3% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 9% vs 1.3% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 5.0% vs 1.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 3.5% vs 0% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 2.6% vs 0.9% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.9% vs 0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 7.6% vs 0% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 2.1% vs 0% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 0.3% vs 0% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 16.2% vs 3.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 21.9% vs 1.9% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 22.3% vs 1.3% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 18.1% vs 3.2% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 20.3% vs 5.8% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 14.2% vs 1.9% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 14.8% vs 1.9% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 17.1% vs 2.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 10.5% vs 1.5% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 19.0% vs 3.3% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 10.4% vs 1.3% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 9.1% vs 1.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 7.1% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 4.1% vs 0.9% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.6% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 6.8% vs 0% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 4.6% vs 0% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 2.3% vs 0% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 23.0% vs 16.6% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 28.7% vs 15.4% 5 mg BID · wk 52 · n 366 · Phase 3 · secondary NCT01039688
  • 18.4% vs 11.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 29.2% vs 13.2% 5 mg BID · wk 39 · n 366 · Phase 3 · secondary NCT01039688
  • 30.1% vs 17.0% 5 mg BID · wk 65 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 15.9% 5 mg BID · wk 78 · n 366 · Phase 3 · secondary NCT01039688
  • 19.9% vs 5.5% 5 mg BID · wk 13 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 17.6% 5 mg BID · wk 91 · n 366 · Phase 3 · secondary NCT01039688
  • 16.2% vs 3.3% 5 mg BID · wk 8.67 · n 366 · Phase 3 · secondary NCT01039688
  • 5.2% vs 0.6% 5 mg BID · wk 4.33 · n 366 · Phase 3 · secondary NCT01039688
  • 34.1% vs 15.4% 5 mg BID · wk 104 · n 366 · Phase 3 · secondary NCT01039688
  • 23.5% vs 16.6% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 15.4% 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • 21.9% vs 11.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 13.2% 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • 37.9% vs 17.0% 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • 36.6% vs 15.9% 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • 26.6% vs 5.5% 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • 36.8% vs 17.6% 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • 23.0% vs 3.3% 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • 9.2% vs 0.6% 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • 37.6% vs 15.4% 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • 22.4% vs 11.8% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 21.1% vs 9.8% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 18.4% vs 8.8% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 23.9% vs 13.7% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 20.4% vs 0% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 18.3% vs 9.8% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 26.9% vs 1.9% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 14.3% vs 3.4% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 18.3% vs 5.8% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 16.3% vs 1.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 25% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 5.8% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 8.9% vs 8.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 4.1% vs 1.7% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 16.9% vs 4.3% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 13.1% vs 3.1% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 17.3% vs 0% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 1.7% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 14.8% vs 0% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 0% vs 1.4% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 1.5% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 1.9% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 11.1% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 4.9% vs 1.5% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 1.6% vs 0% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 37.7% vs 11.8% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 31.1% vs 8.8% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 24.3% vs 13.7% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.5% vs 0% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 49.1% vs 1.9% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 24.6% vs 3.4% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 12.2% vs 5.8% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 37.7% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 16.2% vs 5.8% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 9.5% vs 4.3% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 26.4% vs 0% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 11.5% vs 1.7% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 9.4% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 3.3% vs 0% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 27.4% vs 8.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 27.5% vs 3.1% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 21.7% vs 1.5% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 10.1% vs 1.5% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 28.4% vs 9.8% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 28.4% vs 13.7% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 22.4% vs 9.8% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 23.8% vs 5.8% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 17.5% vs 5.8% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 4.3% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 1.4% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 2.5% vs 0% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 26.2% vs 1.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 18.0% vs 1.7% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 26.9% vs 3.6% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 19.7% vs 1.7% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 7.7% vs 0% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 14.9% vs 1.4% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 33.3% vs 11.8% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 9.8% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 31.6% vs 8.8% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 28% vs 13.7% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 33.3% vs 0% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 9.8% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 51.9% vs 1.9% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 26.3% vs 3.4% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 5.8% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 21.1% vs 1.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 40.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 24.6% vs 1.7% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 5.8% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 14.3% vs 8.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 17.5% vs 1.7% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 4.3% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 21.7% vs 3.1% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 16.7% vs 0% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 8.8% vs 1.7% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 13.3% vs 1.4% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 17.4% vs 1.5% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 7.4% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 6.7% vs 0% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 4.3% vs 1.5% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 23.5% vs 11.8% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 23.6% vs 9.8% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 8.8% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 29.1% vs 13.7% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 26.5% vs 0% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 21.8% vs 9.8% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 13.2% vs 1.9% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 11.8% vs 3.4% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.6% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 20.6% vs 5.8% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 7.8% vs 1.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 3.9% vs 1.7% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 3.6% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 14.7% vs 5.8% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 2.0% vs 1.7% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 4.3% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 3.8% vs 0% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 5.9% vs 1.7% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 7.3% vs 1.4% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 3.7% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.5% vs 0% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 8.1% vs 11.8% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 9.8% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 8.8% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 20.4% vs 13.7% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 0% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 16.3% vs 9.8% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 7.5% vs 1.9% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 5.6% vs 3.4% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 3.6% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 5.8% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 5.7% vs 1.9% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 9.3% vs 1.7% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 3.6% vs 3.6% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 8.6% vs 5.8% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 1.4% vs 4.3% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 0% vs 1.7% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 0% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 1.9% vs 0% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 34.8% vs 30.4% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 20% vs 19.1% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 3.6% vs 0% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 2.9% vs 1.4% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 6.7% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 23.2% vs 19.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.5% vs 20.1% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.7% vs 21% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.4% vs 16.1% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.6% vs 22.4% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.4% vs 13.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 22.2% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 7.8% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 24% vs 22.6% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.7% vs 23.6% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.4% vs 24.7% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.5% vs 24.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 24.2% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.5% vs 23.3% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.8% vs 23.6% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 21.5% vs 20.5% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.6% vs 16.4% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 14.8% vs 13.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.9% vs 11% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 8.8% vs 8.1% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.4% vs 6.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 4% vs 4.4% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.7% vs 2.4% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.5% vs 1% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.1% vs 0.3% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.6% vs 19.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.2% vs 20.1% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 21% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 22.7% vs 16.1% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.2% vs 22.4% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.4% vs 13.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.4% vs 22.2% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.3% vs 7.8% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.5% vs 22.6% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 23.6% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.3% vs 24.7% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.9% vs 24.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.6% vs 24.2% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 24.8% vs 23.3% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.5% vs 23.6% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 20.5% vs 20.5% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 15.7% vs 16.4% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.4% vs 13.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 8.7% vs 8.1% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 5.7% vs 6.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 3.9% vs 4.4% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.6% vs 2.4% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 1% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.3% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467

DAS28-CRP remission

filgotinib
54.5% vs 50.8%+3.7 vs placebo200 mg · wk 52 · n 475NCT02889796
35 other results
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 48.4% vs 16.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
tofacitinib
23.0% vs 5.2%+17.8 vs placebo5 mg · wk 26 · n 309NCT00847613
174 other results
  • 20.4% vs 5.2% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 11.3% vs 2.0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 36.4% vs 5.2% 10 mg · wk 26 · n 308 · Phase 3 · secondary NCT00847613
  • 26.9% vs 5.2% 10 mg · wk 13 · n 308 · Phase 3 · secondary NCT00847613
  • 9.1% vs 2.0% 10 mg · wk 4.33 · n 308 · Phase 3 · secondary NCT00847613
  • 36.5% vs 20.6% 5 mg BID · wk 52 · n 367 · Phase 3 · secondary NCT01039688
  • 36.2% vs 17.4% 5 mg BID · wk 39 · n 367 · Phase 3 · secondary NCT01039688
  • 37.6% vs 19.6% 5 mg BID · wk 65 · n 367 · Phase 3 · secondary NCT01039688
  • 31.3% vs 15.2% 5 mg BID · wk 26 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 19.0% 5 mg BID · wk 78 · n 367 · Phase 3 · secondary NCT01039688
  • 25.9% vs 9.8% 5 mg BID · wk 13 · n 367 · Phase 3 · secondary NCT01039688
  • 37.1% vs 17.4% 5 mg BID · wk 91 · n 367 · Phase 3 · secondary NCT01039688
  • 20.4% vs 5.4% 5 mg BID · wk 8.67 · n 367 · Phase 3 · secondary NCT01039688
  • 7.4% vs 2.7% 5 mg BID · wk 4.33 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 18.5% 5 mg BID · wk 104 · n 367 · Phase 3 · secondary NCT01039688
  • 49.5% vs 20.6% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 45.7% vs 17.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 19.6% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 47.2% vs 15.2% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 19.0% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 37.8% vs 9.8% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 17.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 28.7% vs 5.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 14.1% vs 2.7% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 43.9% vs 18.5% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 65.9% vs 30% 5 mg · wk 24 · n 40 · Phase 2 · secondary NCT00550446
  • 22% vs 15% 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • 41.5% vs 19.4% 5 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 68.9% vs 16.7% 5 mg · wk 20 · n 40 · Phase 2 · secondary NCT00550446
  • 20% vs 5.6% 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • 35.1% vs 13.9% 5 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 69.6% vs 35% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT00550446
  • 28.3% vs 15% 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • 24.1% vs 8.1% 5 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 6.7% 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT00550446
  • 24.4% vs 6.7% 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • 16.7% vs 6.7% 5 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 65.8% vs 3.3% 5 mg · wk 10 · n 40 · Phase 2 · secondary NCT00550446
  • 21.7% vs 4.3% 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • 66.7% vs 9.7% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT00550446
  • 14.9% vs 4.4% 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • 19.4% vs 6.9% 5 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 56.4% vs 5.9% 5 mg · wk 6 · n 40 · Phase 2 · secondary NCT00550446
  • 8.9% vs 1.9% 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • 13.6% vs 3.5% 5 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT00550446
  • 4.4% vs 1.9% 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • 8.1% vs 3.3% 5 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 62.5% vs 2.7% 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT00550446
  • 4.2% vs 0% 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 5 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 72.7% vs 30% 10 mg · wk 24 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT00550446
  • 36.5% vs 19.4% 10 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 88.7% vs 16.7% 10 mg · wk 20 · n 45 · Phase 2 · secondary NCT00550446
  • 43.4% vs 5.6% 10 mg · wk 20 · n 60 · Phase 2 · secondary NCT00550446
  • 37.1% vs 13.9% 10 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 78.2% vs 35% 10 mg · wk 16 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 16 · n 60 · Phase 2 · secondary NCT00550446
  • 30.2% vs 8.1% 10 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 75.6% vs 6.7% 10 mg · wk 12 · n 45 · Phase 2 · secondary NCT00550446
  • 33.3% vs 6.7% 10 mg · wk 12 · n 60 · Phase 2 · secondary NCT00550446
  • 32.3% vs 6.7% 10 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 90.7% vs 3.3% 10 mg · wk 10 · n 45 · Phase 2 · secondary NCT00550446
  • 31.6% vs 4.3% 10 mg · wk 10 · n 60 · Phase 2 · secondary NCT00550446
  • 78.6% vs 9.7% 10 mg · wk 8 · n 45 · Phase 2 · secondary NCT00550446
  • 21.4% vs 4.4% 10 mg · wk 8 · n 60 · Phase 2 · secondary NCT00550446
  • 21.3% vs 6.9% 10 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 79.5% vs 5.9% 10 mg · wk 6 · n 45 · Phase 2 · secondary NCT00550446
  • 24.1% vs 1.9% 10 mg · wk 6 · n 60 · Phase 2 · secondary NCT00550446
  • 24.2% vs 3.5% 10 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 83.7% vs 5.7% 10 mg · wk 4 · n 45 · Phase 2 · secondary NCT00550446
  • 17.5% vs 1.9% 10 mg · wk 4 · n 60 · Phase 2 · secondary NCT00550446
  • 19.1% vs 3.3% 10 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 71.1% vs 2.7% 10 mg · wk 2 · n 45 · Phase 2 · secondary NCT00550446
  • 5% vs 0% 10 mg · wk 2 · n 60 · Phase 2 · secondary NCT00550446
  • 4.4% vs 3.3% 10 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 32.7% vs 19.4% 20 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 30.9% vs 13.9% 20 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.1% vs 8.1% 20 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 24.6% vs 6.7% 20 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 20.9% vs 6.9% 20 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 10.1% vs 3.5% 20 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 10% vs 3.3% 20 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 4.0% vs 3.3% 20 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 84.6% vs 30% 15 mg · wk 24 · n 39 · Phase 2 · secondary NCT00550446
  • 50% vs 15% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 39.3% vs 19.4% 15 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 76.9% vs 16.7% 15 mg · wk 20 · n 39 · Phase 2 · secondary NCT00550446
  • 42.3% vs 5.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 38.6% vs 13.9% 15 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 82.4% vs 35% 15 mg · wk 16 · n 39 · Phase 2 · secondary NCT00550446
  • 43.1% vs 15% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 37.9% vs 8.1% 15 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 68.6% vs 6.7% 15 mg · wk 12 · n 39 · Phase 2 · secondary NCT00550446
  • 40.4% vs 6.7% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 37.1% vs 6.7% 15 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 79.4% vs 3.3% 15 mg · wk 10 · n 39 · Phase 2 · secondary NCT00550446
  • 38.5% vs 4.3% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 75% vs 9.7% 15 mg · wk 8 · n 39 · Phase 2 · secondary NCT00550446
  • 41.5% vs 4.4% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 23.9% vs 6.9% 15 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 67.6% vs 5.9% 15 mg · wk 6 · n 39 · Phase 2 · secondary NCT00550446
  • 32.7% vs 1.9% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 22.7% vs 3.5% 15 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 15 mg · wk 4 · n 39 · Phase 2 · secondary NCT00550446
  • 15.1% vs 1.9% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 16.9% vs 3.3% 15 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 66.7% vs 2.7% 15 mg · wk 2 · n 39 · Phase 2 · secondary NCT00550446
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 13.2% vs 3.3% 15 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 46.4% vs 30% 3 mg · wk 24 · n 33 · Phase 2 · secondary NCT00550446
  • 39.3% vs 15% 3 mg · wk 24 · n 50 · Phase 2 · secondary NCT00550446
  • 35.7% vs 19.4% 3 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 58.6% vs 16.7% 3 mg · wk 20 · n 33 · Phase 2 · secondary NCT00550446
  • 20.7% vs 5.6% 3 mg · wk 20 · n 50 · Phase 2 · secondary NCT00550446
  • 43.2% vs 13.9% 3 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 35% 3 mg · wk 16 · n 33 · Phase 2 · secondary NCT00550446
  • 30% vs 15% 3 mg · wk 16 · n 50 · Phase 2 · secondary NCT00550446
  • 41.9% vs 8.1% 3 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 42.9% vs 6.7% 3 mg · wk 12 · n 33 · Phase 2 · secondary NCT00550446
  • 8.9% vs 6.7% 3 mg · wk 12 · n 50 · Phase 2 · secondary NCT00550446
  • 30.9% vs 6.7% 3 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 3.3% 3 mg · wk 10 · n 33 · Phase 2 · secondary NCT00550446
  • 8.5% vs 4.3% 3 mg · wk 10 · n 50 · Phase 2 · secondary NCT00550446
  • 46.7% vs 9.7% 3 mg · wk 8 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 4.4% 3 mg · wk 8 · n 50 · Phase 2 · secondary NCT00550446
  • 22.0% vs 6.9% 3 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 43.3% vs 5.9% 3 mg · wk 6 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 1.9% 3 mg · wk 6 · n 50 · Phase 2 · secondary NCT00550446
  • 19.7% vs 3.5% 3 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 5.7% 3 mg · wk 4 · n 33 · Phase 2 · secondary NCT00550446
  • 6.5% vs 1.9% 3 mg · wk 4 · n 50 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.3% 3 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 2.7% 3 mg · wk 2 · n 33 · Phase 2 · secondary NCT00550446
  • 4% vs 0% 3 mg · wk 2 · n 50 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.3% 3 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 30% 1 mg · wk 24 · n 43 · Phase 2 · secondary NCT00550446
  • 16.7% vs 15% 1 mg · wk 24 · n 53 · Phase 2 · secondary NCT00550446
  • 23.1% vs 19.4% 1 mg · wk 24 · n 64 · Phase 2 · secondary NCT00413660
  • 46.2% vs 16.7% 1 mg · wk 20 · n 43 · Phase 2 · secondary NCT00550446
  • 19.2% vs 5.6% 1 mg · wk 20 · n 53 · Phase 2 · secondary NCT00550446
  • 20.5% vs 13.9% 1 mg · wk 20 · n 64 · Phase 2 · secondary NCT00413660
  • 48.1% vs 35% 1 mg · wk 16 · n 43 · Phase 2 · secondary NCT00550446
  • 22.2% vs 15% 1 mg · wk 16 · n 53 · Phase 2 · secondary NCT00550446
  • 14.3% vs 8.1% 1 mg · wk 16 · n 64 · Phase 2 · secondary NCT00413660
  • 22.2% vs 6.7% 1 mg · wk 12 · n 43 · Phase 2 · secondary NCT00550446
  • 9.3% vs 6.7% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00550446
  • 6.6% vs 6.7% 1 mg · wk 12 · n 64 · Phase 2 · secondary NCT00413660
  • 26.3% vs 3.3% 1 mg · wk 10 · n 43 · Phase 2 · secondary NCT00550446
  • 10.9% vs 4.3% 1 mg · wk 10 · n 53 · Phase 2 · secondary NCT00550446
  • 25.6% vs 9.7% 1 mg · wk 8 · n 43 · Phase 2 · secondary NCT00550446
  • 2.1% vs 4.4% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00550446
  • 7.9% vs 6.9% 1 mg · wk 8 · n 64 · Phase 2 · secondary NCT00413660
  • 20.5% vs 5.9% 1 mg · wk 6 · n 43 · Phase 2 · secondary NCT00550446
  • 8.5% vs 1.9% 1 mg · wk 6 · n 53 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.5% 1 mg · wk 6 · n 64 · Phase 2 · secondary NCT00413660
  • 30% vs 5.7% 1 mg · wk 4 · n 43 · Phase 2 · secondary NCT00550446
  • 6% vs 1.9% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00550446
  • 4.6% vs 3.3% 1 mg · wk 4 · n 64 · Phase 2 · secondary NCT00413660
  • 25.6% vs 2.7% 1 mg · wk 2 · n 43 · Phase 2 · secondary NCT00550446
  • 1.9% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 1 mg · wk 2 · n 64 · Phase 2 · secondary NCT00413660
  • 16.7% vs 19.4% 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • 0% vs 13.9% 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • 11.1% vs 8.1% 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • 15.4% vs 19.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 15.4% vs 13.9% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 23.1% vs 8.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 25% vs 19.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 28.6% vs 13.9% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 9.5% vs 8.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 24% vs 22.4% 11mg MR · wk 24 · n 100 · Phase 2 · secondary NCT04413617
  • 40.8% vs 22.4% 400mg MR + 11mg MR · wk 24 · n 103 · Phase 2 · secondary NCT04413617

HAQ-DI, change

filgotinib
-0.9 vs -0.7−0.2 vs placebo200 mg · wk 52 · n 475NCT02889796
36 other results
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181
tofacitinib
-0.5 vs -0.2−0.3 vs placebo5 mg · wk 13 · n 240NCT00814307
233 other results
  • -0.5 vs -0.2 5 mg · wk 13 · n 311 · Phase 3 · primary NCT00856544
  • -0.5 vs -0.2 5 mg twice daily · wk 13 · n 201 · Phase 3 · primary NCT00853385
  • -0.3 vs -0.1 5 mg · wk 13 · n 315 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 5 mg · wk 13 · n 132 · Phase 3 · primary NCT00960440
  • -0.5 vs -0.2 10 mg · wk 13 · n 241 · Phase 3 · primary NCT00814307
  • -0.5 vs -0.2 10 mg · wk 13 · n 315 · Phase 3 · primary NCT00856544
  • -0.6 vs -0.2 10 mg twice daily · wk 13 · n 199 · Phase 3 · primary NCT00853385
  • -0.4 vs -0.1 10 mg · wk 13 · n 309 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 10 mg · wk 13 · n 134 · Phase 3 · primary NCT00960440
  • -0.9 vs -0.7 5 mg BID · wk 52 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.7 5 mg BID · wk 39 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 65 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.6 5 mg BID · wk 26 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 78 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 5 mg BID · wk 13 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 91 · n 365 · Phase 3 · secondary NCT01039688
  • -0.7 vs -0.3 5 mg BID · wk 8.67 · n 365 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.2 5 mg BID · wk 4.33 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 104 · n 365 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.6 10 mg BID · wk 26 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • -1 vs -0.7 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.3 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • -0.6 vs -0.2 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.4 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.3 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 5 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs 0.2 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 5 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.2 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.2 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.0 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 5 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 5 mg BID · wk 8 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.2 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 5 mg BID · wk 6 · n 59 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.0 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 5 mg BID · wk 4 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs 0.1 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • -0.2 vs -0.0 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.0 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 5 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 5 mg BID · wk 2 · n 59 · Phase 2 · secondary NCT00147498
  • -0.1 vs 0 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg BID · wk 1 · n 59 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.4 10 mg · wk 24 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 20 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 16 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.3 10 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.2 10 mg · wk 12 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.2 10 mg · wk 10 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.5 vs -0.2 10 mg · wk 8 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.2 10 mg · wk 6 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 10 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.1 10 mg · wk 4 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.1 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 10 mg · wk 2 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 20 mg · wk 4 · n 79 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.1 20 mg · wk 2 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 10 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.0 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 10 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 30 mg BID · wk 8 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 30 mg BID · wk 6 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.1 30 mg BID · wk 4 · n 64 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.1 30 mg BID · wk 2 · n 64 · Phase 2 · secondary NCT00147498
  • -0.4 vs -0.1 30 mg BID · wk 1 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.4 20 mg · wk 24 · n 79 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.4 20 mg · wk 20 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 20 mg · wk 16 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 20 mg · wk 8 · n 79 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 20 mg · wk 6 · n 79 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • -0.8 vs -0.4 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 15 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • -0.8 vs -0.2 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 15 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.8 vs -0.2 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • -0.7 vs -0.2 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 15 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 15 mg BID · wk 8 · n 68 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 15 mg BID · wk 6 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs 0.0 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.1 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 15 mg BID · wk 4 · n 68 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.1 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.0 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 15 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 15 mg BID · wk 2 · n 68 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.1 15 mg BID · wk 1 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs -0.4 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 3 mg · wk 24 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 3 mg · wk 20 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.3 3 mg · wk 16 · n 66 · Phase 2 · secondary NCT00413660
  • -0.4 vs 0.2 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 3 mg · wk 12 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.2 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs 0.0 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 8 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 6 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0.0 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 4 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.0 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 3 mg · wk 2 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.6 vs -0.4 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 1 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.2 vs 0.2 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 1 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs 0.2 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.0 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 1 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 1 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.0 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.1 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 1 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.0 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • -0.1 vs -0.0 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • -0.1 vs -0.1 1 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • 0.1 vs -0.1 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • -0.4 vs -0.0 wk 6 · n 93 · Phase 1 · secondary NCT01484561
  • -0.5 vs -0.4 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.4 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.4 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.3 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.3 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.5 5 mg BID · wk 52 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 39 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 65 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 26 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 78 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 5 mg BID · wk 13 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 91 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.4 vs -0.4 5 mg BID · wk 8.67 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 104 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 117 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 130 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 143 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 156 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 169 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 182 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 195 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 208 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 221 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 234 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 247 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 260 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 273 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 52 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 39 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 65 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 26 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 78 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 13 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 91 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 8.67 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 104 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 117 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 130 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 143 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 156 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 169 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 182 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 195 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 208 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 221 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 234 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 247 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 260 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 273 · n 1390 · Phase 4 · secondary NCT02092467

Modified Sharp score, change

filgotinib
0.2 vs 0.9−0.7 vs placebo200 mg · wk 52 · n 468NCT02889796
9 other results
  • 0.1 vs 0.4 200 mg · wk 24 · n 467 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
tofacitinib
0.1 vs 0.5−0.3 vs placebo5 mg · wk 26 · n 286NCT00847613
7 other results
  • 0.1 vs 0.5 10 mg · wk 26 · n 295 · Phase 3 · primary NCT00847613
  • 0.2 vs 0.7 5 mg BID · wk 24 · n 346 · Phase 3 · primary NCT01039688
  • 0.1 vs 0.7 10 mg BID · wk 24 · n 370 · Phase 3 · primary NCT01039688
  • 0.4 vs 1.2 5 mg BID · wk 52 · n 346 · Phase 3 · secondary NCT01039688
  • 0.6 vs 2.1 5 mg BID · wk 104 · n 346 · Phase 3 · secondary NCT01039688
  • 0.2 vs 1.2 10 mg BID · wk 52 · n 371 · Phase 3 · secondary NCT01039688
  • 0.3 vs 2.1 10 mg BID · wk 104 · n 371 · Phase 3 · secondary NCT01039688
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
23 other shared endpoints and safety

Coverage. filgotinib: 27 of 27 rows · tofacitinib: 27 of 27 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfilgotinib
Rows use multiple source trials
tofacitinib
Rows use multiple source trials
ACR/EULAR Remission
responder rate · % of participants
No placebo or comparator arm
17.7% (n=497) @ 48wka,b,c,d
NCT02065700 · Phase 2 · registry result, not featured evidence
show 3 more doses
20.7% (n=497) @ 48wk
NCT02065700 · Phase 2 · registry result, not featured evidence
14% (n=242) @ 48wk
NCT02065700 · Phase 2 · registry result, not featured evidence
16.7% (n=242) @ 48wk
NCT02065700 · Phase 2 · registry result, not featured evidence
22.35% (n=264) @ 48wk11 mga,b,c,d
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
23.68% (n=266) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
ACR20
responder rate · % of participants
No placebo or comparator arm
36.6% (n=497) @ 288wka,e,c,d
NCT02065700 · Phase 2 · registry result, not featured evidence
show 3 more doses
87.9% (n=497) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
38.8% (n=242) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
85.5% (n=242) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
100% (n=381) @ 288wk5 mg BIDa,e,c,d
NCT00661661 · Phase 3 · registry result, not featured evidence
show 1 more dose
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
ACR50
responder rate · % of participants
No placebo or comparator arm
29.8% (n=497) @ 288wka,e,c,d
NCT02065700 · Phase 2 · registry result, not featured evidence
show 3 more doses
70.8% (n=497) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
33.5% (n=242) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
73.6% (n=242) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
100% (n=381) @ 288wk5 mg BIDa,e,c,d
NCT00661661 · Phase 3 · registry result, not featured evidence
show 1 more dose
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
ACR70
responder rate · % of participants
No placebo or comparator arm
22.1% (n=497) @ 288wka,e,c,d
NCT02065700 · Phase 2 · registry result, not featured evidence
show 3 more doses
52.4% (n=497) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
24.8% (n=242) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
54.5% (n=242) @ 288wk
NCT02065700 · Phase 2 · registry result, not featured evidence
66.7% (n=381) @ 288wk5 mg BIDa,e,c,d
NCT00661661 · Phase 3 · registry result, not featured evidence
show 1 more dose
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
Boolean Remission
responder rate · % of participants
11.6% (n=86) vs 1.2% (n=86) placebo @ 24wk200 mg QDa,b,c,d,f
NCT01888874 · Phase 2 · registry result, not featured evidence
show 5 more doses
19% (n=84) vs 1.2% (n=86) placebo @ 24wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
8.2% (n=85) vs 1.2% (n=86) placebo @ 24wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5% (n=85) vs 1.2% (n=86) placebo @ 24wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
11% (n=82) vs 1.2% (n=86) placebo @ 24wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.8% (n=86) vs 1.2% (n=86) placebo @ 24wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
8.33% (n=1455) vs 13.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d,f
NCT02092467 · Phase 4
show 1 more dose
22.22% (n=1456) vs 13.33% (n=1451) TNFi @ 312wk10 mg BID
NCT02092467 · Phase 4
CDAI
absolute change · score
-33.6 vs -31.2 MTX score @ 52wk200 mga,g,c
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
-33.8 vs -31.2 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-31.9 vs -31.2 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
-28.52 vs -27.73 TNFi score @ 52wk5 mg BIDa,g,c
NCT02092467 · Phase 4
show 1 more dose
-29.38 vs -27.73 TNFi score @ 52wk10 mg BID
NCT02092467 · Phase 4
CDAI
absolute change · score
No placebo or comparator arm
-28.102 score @ 24wk200 mg QDa,b,c,d,h
NCT01894516 · Phase 2 · registry result, not featured evidence
show 2 more doses
-29.502 score @ 24wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
-22.278 score @ 24wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.97 score @ 48wk11 mga,b,c,d,h
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
0.84 score @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
CRP Change
absolute change · mg
-10.87 vs -1.5 placebo mg @ 24wk200 mga,i,c,d
NCT02873936 · Phase 3
show 1 more dose
-11.12 vs -1.5 placebo mg @ 24wk100 mg
NCT02873936 · Phase 3
-19.43 vs -4.18 placebo mg @ 24wk5 mga,i,c,d
NCT00550446 · Phase 2 · registry result, not featured evidence
show 4 more doses
-10.5 vs -4.18 placebo mg @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
-20.43 vs -4.18 placebo mg @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
-2.25 vs -4.18 placebo mg @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
-4.19 vs -4.18 placebo mg @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
DAS Low Disease Activity
responder rate · % of participants
65.7% (n=210) vs 47.6% (n=416) MTX @ 52wk200 mga,c
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
69% (n=416) vs 47.6% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
59.9% (n=207) vs 47.6% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
52.59% (n=367) vs 32.61% (n=184) MTX @ 52wk5 mg BIDa,c
NCT01039688 · Phase 3
show 3 more doses
33.33% (n=342) vs 18.71% (n=171) MTX @ 52wk5 mg BID
NCT01039688 · Phase 3
64.97% (n=394) vs 32.61% (n=184) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
41.13% (n=372) vs 18.71% (n=171) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
DAS28-CRP
absolute change · score
-3.3 vs -2.8 MTX score @ 52wk200 mga,c
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
-3.4 vs -2.8 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-3.1 vs -2.8 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
-2.52 vs -1.99 MTX score @ 52wk5 mg BIDa,c
NCT01039688 · Phase 3
show 1 more dose
-2.85 vs -1.99 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
FACIT - Fatigue
absolute value · score
39.8 vs 39.4 placebo score @ 52wk200 mga,c,d
NCT02889796 · Phase 3
show 1 more dose
39.8 vs 39.4 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
37.85 vs 35.99 MTX score @ 52wk5 mg BIDa,c,d
NCT01039688 · Phase 3
show 1 more dose
38.95 vs 35.99 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
FACIT-Fatigue
absolute change · score
11.5 vs 11.3 MTX score @ 52wk200 mga,c
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
11.7 vs 11.3 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
11.9 vs 11.3 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
8.75 vs 6.89 MTX score @ 52wk5 mg BIDa,c
NCT01039688 · Phase 3
show 1 more dose
9.18 vs 6.89 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
FACIT-Fatigue
absolute change · score
No placebo or comparator arm
13.7 score @ 24wk200 mg QDa,e,c,d
NCT01894516 · Phase 2 · registry result, not featured evidence
show 2 more doses
11.3 score @ 24wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
10 score @ 24wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
34.58 score @ 24wk5 mga,e,c,d
NCT00814307 · Phase 3
show 1 more dose
36.3 score @ 24wk10 mg
NCT00814307 · Phase 3
HAQ-DI
responder rate · % of participants
75.8% (n=475) vs 81.6% (n=190) placebo @ 52wk200 mga,c,d
NCT02889796 · Phase 3
show 1 more dose
73% (n=480) vs 81.6% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
68.03% (n=366) vs 58.7% (n=184) MTX @ 52wk5 mg BIDa,c,d
NCT01039688 · Phase 3
show 5 more doses
65.03% (n=366) vs 52.72% (n=184) MTX @ 52wk5 mg BID
NCT01039688 · Phase 3
59.56% (n=366) vs 45.65% (n=184) MTX @ 52wk5 mg BID
NCT01039688 · Phase 3
71.43% (n=392) vs 58.7% (n=184) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
67.35% (n=392) vs 52.72% (n=184) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
63.01% (n=392) vs 45.65% (n=184) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
Patient Assessment of Arthritis Pain
absolute change · score
-30 vs -14 placebo score @ 12wk200 mga,i,c,d
NCT02873936 · Phase 3
show 1 more dose
-27 vs -14 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-34.37 vs -1.06 placebo score @ 12wk5 mga,i,c,d
NCT00687193 · Phase 2 · registry result, not featured evidence
show 4 more doses
-42.91 vs -1.06 placebo score @ 12wk10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-43.79 vs -1.06 placebo score @ 12wk15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-22.33 vs -1.06 placebo score @ 12wk3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-18.38 vs -1.06 placebo score @ 12wk1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
Patient Global Assessment
absolute change · score
-31 vs -14 placebo score @ 12wk200 mga,i,c,d
NCT02873936 · Phase 3
show 1 more dose
-27 vs -14 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-34.59 vs -1.02 placebo score @ 12wk5 mga,i,c,d
NCT00687193 · Phase 2 · registry result, not featured evidence
show 4 more doses
-43.55 vs -1.02 placebo score @ 12wk10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-41.86 vs -1.02 placebo score @ 12wk15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-20.91 vs -1.02 placebo score @ 12wk3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-16.29 vs -1.02 placebo score @ 12wk1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
Physician Global Assessment
absolute change · score
-53 vs -41 placebo score @ 24wk200 mga,i,c
NCT02873936 · Phase 3
show 1 more dose
-45 vs -41 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
-47.31 vs -43.42 PF-06651600 score @ 24wk11mg MRa,i,c
NCT04413617 · Phase 2 · registry result, not featured evidence
show 1 more dose
-47.5 vs -43.42 PF-06651600 score @ 24wk400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
SDAI
absolute change · score
-35 vs -32 MTX score @ 52wk200 mga,g,c
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
-35.2 vs -32 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-33 vs -32 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
-29.56 vs -28.71 TNFi score @ 52wk5 mg BIDa,g,c
NCT02092467 · Phase 4
show 1 more dose
-30.46 vs -28.71 TNFi score @ 52wk10 mg BID
NCT02092467 · Phase 4
SDAI
absolute change · score
No placebo or comparator arm
-29.564 score @ 24wk200 mg QDa,b,c,d,h
NCT01894516 · Phase 2 · registry result, not featured evidence
show 2 more doses
-30.983 score @ 24wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
-23.16 score @ 24wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
3.16 score @ 48wk11 mga,b,c,d,h
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
0.94 score @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
SF-36 MCS
absolute change · score
6.1 vs 6.5 MTX score @ 52wk200 mga,c
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
6.2 vs 6.5 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
6.8 vs 6.5 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
6.21 vs 4.72 MTX score @ 52wk5 mg BIDa,c
NCT01039688 · Phase 3
show 1 more dose
6.62 vs 4.72 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
SF-36 MCS
absolute value · score
50.6 vs 50.8 placebo score @ 52wk200 mga,c,d
NCT02889796 · Phase 3
show 1 more dose
51.5 vs 50.8 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
47.04 vs 45.71 MTX score @ 52wk5 mg BIDa,c,d
NCT01039688 · Phase 3
show 1 more dose
48.05 vs 45.71 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
SF-36 PCS
absolute change · score
11.9 vs 11.2 MTX score @ 52wk200 mga,c
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
13.4 vs 11.2 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
12 vs 11.2 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
10.3 vs 7.48 MTX score @ 52wk5 mg BIDa,c
NCT01039688 · Phase 3
show 1 more dose
12.35 vs 7.48 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
SF-36 PCS
absolute value · score
45.6 vs 45.1 placebo score @ 52wk200 mga,c,d
NCT02889796 · Phase 3
show 1 more dose
45.1 vs 45.1 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
43.65 vs 41.27 MTX score @ 52wk5 mg BIDa,c,d
NCT01039688 · Phase 3
show 1 more dose
45.72 vs 41.27 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
Dropout rate
8.8%200 mgj
NCT02873936 · Phase 3
show 26 more results
15%100 mg
NCT02873936 · Phase 3
17.1%200 mg
NCT02886728 · Phase 3 · monotherapy
17.3%200 mg
NCT02886728 · Phase 3 · combination
15.5%100 mg
NCT02886728 · Phase 3 · combination
11.1%200 mg
NCT02889796 · Phase 3
12.1%100 mg
NCT02889796 · Phase 3
52.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53.7%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
61.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
0%Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
67.6%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
66.5%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.3%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
6.9%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
7%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
8.2%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.9%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.3%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
10.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
0%j
NCT01262118 · Phase 1
show 80 more results
4.9%5 mg
NCT00814307 · Phase 3
11%10 mg
NCT00814307 · Phase 3
17.9%5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
20.8%10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
26.5%5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
21.4%10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
n/a: no completion milestone5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
n/a: no completion milestone10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
19.5%5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
23.1%10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—5 mg BID
NCT01039688 · Phase 3
28%10 mg BID
NCT01039688 · Phase 3
27.7%5 mg BID
NCT02092467 · Phase 4
31.5%10 mg BID
NCT02092467 · Phase 4
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
10.2%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
56.9%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
50.8%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
3.8%
NCT02281552 · Phase 3 · registry result, not featured evidence
36.6%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
37.1%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
6.9%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
7.8%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
9.1%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
6.3%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00976599 · Phase 2 · registry result, not featured evidence
—
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
7.5%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.7%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
7.5%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.8%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
8%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.9%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.3%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
9.6%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
18.5%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
17.9%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
25%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.9%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.1%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
9.9%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
10.7%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
12.5%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
12%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
10.3%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
9.9%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.9%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
24.6%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
13%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
9.3%
NCT01484561 · Phase 1 · registry result, not featured evidence
—CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
—Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
2%200 mgj
NCT02873936 · Phase 3
show 26 more results
3.3%100 mg
NCT02873936 · Phase 3
2.4%200 mg
NCT02886728 · Phase 3 · monotherapy
3.1%200 mg
NCT02886728 · Phase 3 · combination
2.4%100 mg
NCT02886728 · Phase 3 · combination
3.6%200 mg
NCT02889796 · Phase 3
1.7%100 mg
NCT02889796 · Phase 3
12.3%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
13.4%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
14%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
12.2%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
33.2%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
42.6%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
1.4%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.2%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
2.4%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
—j
NCT01262118 · Phase 1
show 80 more results
1.2%5 mg
NCT00814307 · Phase 3
3.7%10 mg
NCT00814307 · Phase 3
6.3%5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
9.1%10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
11.8%5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
11.9%10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
11.2%5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
8.2%10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
9%5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
9%10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—5 mg BID
NCT01039688 · Phase 3
9.8%10 mg BID
NCT01039688 · Phase 3
—5 mg BID
NCT02092467 · Phase 4
—10 mg BID
NCT02092467 · Phase 4
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
5.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
25.9%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
23.1%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
2.9%
NCT02281552 · Phase 3 · registry result, not featured evidence
25.9%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
22.9%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
1%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
1%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
7.3%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
3.6%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
—
NCT00976599 · Phase 2 · registry result, not featured evidence
—
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
5.7%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
1.9%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.5%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.7%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
14.3%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
14.3%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.1%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.4%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
5.3%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
5%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
8%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.4%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.4%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.6%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
10.1%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
8.7%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1%
NCT01484561 · Phase 1 · registry result, not featured evidence
—CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
—Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
4.1%200 mgj
NCT02873936 · Phase 3
show 26 more results
5.2%100 mg
NCT02873936 · Phase 3
8.1%200 mg
NCT02886728 · Phase 3 · monotherapy
6.3%200 mg
NCT02886728 · Phase 3 · combination
6.3%100 mg
NCT02886728 · Phase 3 · combination
7.4%200 mg
NCT02889796 · Phase 3
8.3%100 mg
NCT02889796 · Phase 3
24.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
22.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
24.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
25.9%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
3.7%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
12.8%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
14.3%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
16.9%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
19.8%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.8%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.3%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.6%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.4%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
2.3%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
0%j
NCT01262118 · Phase 1
show 80 more results
—5 mg
NCT00814307 · Phase 3
—10 mg
NCT00814307 · Phase 3
—5 mg
NCT00856544 · Phase 3
1.6%5 mg
NCT00856544 · Phase 3
2.2%5 mg
NCT00856544 · Phase 3
2.9%5 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
2.2%10 mg
NCT00856544 · Phase 3
2.8%10 mg
NCT00856544 · Phase 3
2.5%10 mg
NCT00856544 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
4.3%5 mg twice daily
NCT00853385 · Phase 3
4.2%5 mg twice daily
NCT00853385 · Phase 3
5.9%5 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
3.2%10 mg twice daily
NCT00853385 · Phase 3
4%10 mg twice daily
NCT00853385 · Phase 3
5%10 mg twice daily
NCT00853385 · Phase 3
—5 mg
NCT00847613 · Phase 3
5%5 mg
NCT00847613 · Phase 3
3.5%5 mg
NCT00847613 · Phase 3
3.7%5 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
2.3%10 mg
NCT00847613 · Phase 3
3.3%10 mg
NCT00847613 · Phase 3
3.2%10 mg
NCT00847613 · Phase 3
—5 mg
NCT00960440 · Phase 3
4%5 mg
NCT00960440 · Phase 3
1.5%5 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
4%10 mg
NCT00960440 · Phase 3
1.5%10 mg
NCT00960440 · Phase 3
10.7%5 mg BID
NCT01039688 · Phase 3
10.8%10 mg BID
NCT01039688 · Phase 3
25.6%5 mg BID
NCT02092467 · Phase 4
28.8%10 mg BID
NCT02092467 · Phase 4
3.8%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
1.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
2.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
10.4%5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
30.8%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
29.7%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
4.8%
NCT02281552 · Phase 3 · registry result, not featured evidence
29.1%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
26.7%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
2.9%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
0%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
5.5%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
3.6%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00976599 · Phase 2 · registry result, not featured evidence
0%
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.8%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
1.9%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
5.7%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.6%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
7%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.9%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.4%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.7%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.7%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.6%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.6%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.4%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
6%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0%20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
8%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
7.3%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0%3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
2%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.8%1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.6%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
4.3%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
7.2%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
2.1%
NCT01484561 · Phase 1 · registry result, not featured evidence
0%CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
0%Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
200 mgj
nasopharyngitis 10.2% (placebo 4.7%)
bronchitis 5.4% (placebo 5.4%)
headache 5.4% (placebo 1.4%)
NCT02873936 · Phase 3
show 25 more results
100 mg
headache 5.9% (placebo 1.4%)
nasopharyngitis 5.9% (placebo 4.7%)
upper respiratory tract infection 5.9% (placebo 4.1%)
NCT02873936 · Phase 3
200 mg
nasopharyngitis 8.1%
hypertension 7.1%
nausea 7.1%
NCT02886728 · Phase 3 · monotherapy
200 mg
nausea 12.3%
upper respiratory tract infection 10.1%
alanine aminotransferase increased 5.5%
NCT02886728 · Phase 3 · combination
100 mg
nausea 16.9%
nasopharyngitis 8.2%
alopecia 7.2%
NCT02886728 · Phase 3 · combination
200 mg
nasopharyngitis 9.1% (placebo 5.3%)
upper respiratory tract infection 8.6% (placebo 2.9%)
nausea 5.5% (placebo 1.5%)
NCT02889796 · Phase 3
100 mg
upper respiratory tract infection 10.2% (placebo 2.9%)
nasopharyngitis 10% (placebo 5.3%)
alanine aminotransferase increased 5.2% (placebo 2.3%)
NCT02889796 · Phase 3
200 mg
covid-19 18.3%
nasopharyngitis 13.1%
upper respiratory tract infection 11%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
covid-19 17.3%
upper respiratory tract infection 13.1%
rheumatoid arthritis 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 15.3%
nasopharyngitis 15.1%
rheumatoid arthritis 13.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 18.5%
rheumatoid arthritis 12.2%
upper respiratory tract infection 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 7.4% (placebo 7.3%)
dyslipidaemia 3.7% (placebo 0%)
headache 3.7% (placebo 1.8%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
covid-19 15.4% (placebo 0%)
ankylosing spondylitis 7.7% (placebo 0%)
latent tuberculosis 7.7% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 57.1% (placebo 7.3%)
covid-19 42.9% (placebo 0%)
alanine aminotransferase increased 14.3% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
hypertension 15.1%
urinary tract infection 14.5%
nasopharyngitis 14.1%
NCT02065700 · Phase 2 · registry result, not featured evidence
mycobacterium tuberculosis complex test positive 16.5%
upper respiratory tract infection 15.3%
hypercholesterolaemia 12.4%
NCT02065700 · Phase 2 · registry result, not featured evidence
asthenia 9.5% (placebo 0%)
blood creatine phosphokinase increased 4.8% (placebo 0%)
dyspepsia 4.8% (placebo 0%)
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
200 mg QD
anaemia 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 2.8%)
urinary tract infection 5.8% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
100 mg QD
urinary tract infection 8.2% (placebo 1.4%)
hypercholesterolaemia 5.9% (placebo 4.2%)
hypertriglyceridaemia 5.9% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
50 mg QD
headache 5.6% (placebo 1.4%)
hypercholesterolaemia 5.6% (placebo 4.2%)
hypertension 4.2% (placebo 5.6%)
NCT01894516 · Phase 2 · registry result, not featured evidence
200 mg QD
headache 7% (placebo 4.7%)
hypercholesterolaemia 5.8% (placebo 0%)
hypertension 4.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg BID
hypercholesterolaemia 4.8% (placebo 0%)
nasopharyngitis 4.8% (placebo 4.7%)
headache 2.4% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg QD
hypertension 5% (placebo 2.3%)
nasopharyngitis 2.5% (placebo 4.7%)
upper respiratory tract infection 1.7% (placebo 1.2%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg BID
upper respiratory tract infection 5.1% (placebo 1.2%)
vomiting 5.1% (placebo 1.2%)
hypertension 3.4% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 9.8% (placebo 4.7%)
nausea 8.5% (placebo 3.5%)
hypertension 3.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
25 mg BID
headache 7% (placebo 4.7%)
gastroenteritis 5.8% (placebo 0%)
nasopharyngitis 4.7% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence
j
upper respiratory tract infection 19.4%
headache 11.1%
urinary tract infection 8.3%
NCT01262118 · Phase 1
show 70 more results
5 mg
upper respiratory tract infection 4.1% (placebo 0%)
gastroenteritis 2.2% (placebo 0%)
nasopharyngitis 1.9% (placebo 0%)
NCT00856544 · Phase 3
5 mg
upper respiratory tract infection 3.5% (placebo 0%)
diarrhoea 1.9% (placebo 0%)
sinusitis 1.6% (placebo 2.5%)
NCT00856544 · Phase 3
5 mg
upper respiratory tract infection 6% (placebo 0%)
nasopharyngitis 5.1% (placebo 0%)
diarrhoea 4.4% (placebo 0%)
NCT00856544 · Phase 3
10 mg
nasopharyngitis 2.8% (placebo 0%)
upper respiratory tract infection 2.8% (placebo 0%)
oedema peripheral 2.5% (placebo 1.2%)
NCT00856544 · Phase 3
10 mg
upper respiratory tract infection 5.7% (placebo 0%)
blood creatine phosphokinase increased 2.2% (placebo 0%)
urinary tract infection 2.2% (placebo 1.2%)
NCT00856544 · Phase 3
10 mg
upper respiratory tract infection 7.2% (placebo 0%)
diarrhoea 3.1% (placebo 0%)
headache 3.1% (placebo 2.5%)
NCT00856544 · Phase 3
5 mg twice daily
nasopharyngitis 2.2% (placebo 1.7%)
urinary tract infection 2.2% (placebo 0%)
fall 1.7% (placebo 3.4%)
NCT00853385 · Phase 3
5 mg twice daily
upper respiratory tract infection 3.5% (placebo 0%)
nasopharyngitis 3.1% (placebo 1.7%)
bronchitis 2.7% (placebo 0%)
NCT00853385 · Phase 3
5 mg twice daily
upper respiratory tract infection 4.4% (placebo 0%)
headache 3.9% (placebo 0%)
nasopharyngitis 3.9% (placebo 1.7%)
NCT00853385 · Phase 3
10 mg twice daily
back pain 0.9% (placebo 0%)
fall 0.9% (placebo 3.4%)
nasopharyngitis 0.9% (placebo 1.7%)
NCT00853385 · Phase 3
10 mg twice daily
bronchitis 4% (placebo 0%)
abdominal pain upper 2.8% (placebo 0%)
arthralgia 2.8% (placebo 0%)
NCT00853385 · Phase 3
10 mg twice daily
upper respiratory tract infection 3.5% (placebo 0%)
headache 3% (placebo 0%)
herpes zoster 2.5% (placebo 0%)
NCT00853385 · Phase 3
5 mg
upper respiratory tract infection 4.7% (placebo 0%)
nasopharyngitis 3.6% (placebo 4.9%)
bronchitis 0.8% (placebo 0%)
NCT00847613 · Phase 3
5 mg
nasopharyngitis 5.5% (placebo 4.9%)
upper respiratory tract infection 3.2% (placebo 0%)
herpes zoster 2.5% (placebo 0%)
NCT00847613 · Phase 3
5 mg
headache 5.6% (placebo 0%)
nasopharyngitis 4.4% (placebo 4.9%)
hypertension 3.4% (placebo 0%)
NCT00847613 · Phase 3
10 mg
bronchitis 2.5% (placebo 0%)
nasopharyngitis 2.5% (placebo 4.9%)
upper respiratory tract infection 2.5% (placebo 0%)
NCT00847613 · Phase 3
10 mg
nasopharyngitis 5.6% (placebo 4.9%)
urinary tract infection 4.3% (placebo 0%)
upper respiratory tract infection 3.8% (placebo 0%)
NCT00847613 · Phase 3
10 mg
nasopharyngitis 4.1% (placebo 4.9%)
cough 2.8% (placebo 0%)
diarrhoea 2.5% (placebo 0%)
NCT00847613 · Phase 3
5 mg
rheumatoid arthritis 3.5% (placebo 3%)
bronchitis 3% (placebo 0%)
nasopharyngitis 3% (placebo 3%)
NCT00960440 · Phase 3
5 mg
diarrhoea 6% (placebo 3.8%)
nasopharyngitis 3.8% (placebo 3%)
upper respiratory tract infection 3.8% (placebo 3%)
NCT00960440 · Phase 3
10 mg
upper respiratory tract infection 4% (placebo 3%)
nasopharyngitis 2.5% (placebo 3%)
back pain 2% (placebo 1.5%)
NCT00960440 · Phase 3
10 mg
headache 6% (placebo 0.8%)
nasopharyngitis 4.5% (placebo 3%)
diarrhoea 3.7% (placebo 3.8%)
NCT00960440 · Phase 3
5 mg BID
upper respiratory tract infection 8%
nasopharyngitis 7.5%
nausea 7.2%
NCT01039688 · Phase 3
10 mg BID
nasopharyngitis 9.8%
blood creatine phosphokinase increased 9.1%
upper respiratory tract infection 9.1%
NCT01039688 · Phase 3
5 mg BID
upper respiratory tract infection 21.9%
bronchitis 15.2%
urinary tract infection 13.1%
NCT02092467 · Phase 4
10 mg BID
upper respiratory tract infection 21.8%
bronchitis 16.7%
urinary tract infection 15.1%
NCT02092467 · Phase 4
11 mg
arthralgia 2.7%
alanine aminotransferase increased 1.9%
aspartate aminotransferase increased 1.9%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
11 mg
alanine aminotransferase increased 3.8%
bronchitis 2.6%
nasopharyngitis 2.6%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
11 mg
nasopharyngitis 5%
upper respiratory tract infection 4.8%
nausea 2.9%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
5 mg
bronchitis 1 6.3%
alanine aminotransferase increased 0%
anemia 0%
NCT00413699 · Phase 3 · registry result, not featured evidence
5 mg BID
upper respiratory tract infection 20.3%
urinary tract infection 14.3%
bronchitis 12.6%
NCT00413699 · Phase 3 · registry result, not featured evidence
10 mg BID
upper respiratory tract infection 18.3%
nasopharyngitis 15.4%
urinary tract infection 13.3%
NCT00413699 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.6%
NCT02281552 · Phase 3 · registry result, not featured evidence
5 mg BID
nasopharyngitis 58%
herpes zoster 15.5%
fall 13.4%
NCT00661661 · Phase 3 · registry result, not featured evidence
10 mg BID
nasopharyngitis 68.6%
herpes zoster 21%
fall 19%
NCT00661661 · Phase 3 · registry result, not featured evidence
11mg MR
sars-cov-2 test positive 6.9%
urinary tract infection 4.9%
headache 3.9%
NCT04413617 · Phase 2 · registry result, not featured evidence
400mg MR + 11mg MR
urinary tract infection 6.8%
sars-cov-2 test positive 3.9%
headache 2.9%
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
5 mg Twice a Day
arthralgia 5.5% (placebo 0%)
rheumatoid arthritis 5.5% (placebo 15.8%)
NCT02147587 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 5.4% (placebo 7.2%)
headache 4.5% (placebo 0.9%)
dizziness 2.7% (placebo 0%)
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
fatigue 13.3% (placebo 0%)
hypoaesthesia 13.3% (placebo 0%)
nausea 13.3% (placebo 7.1%)
NCT00976599 · Phase 2 · registry result, not featured evidence
dyspepsia 4% (placebo 2.1%)
oedema peripheral 4% (placebo 4.3%)
oropharyngeal pain 4% (placebo 0%)
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
5 mg
nasopharyngitis 11.5% (placebo 11.5%)
hypertension 5.8% (placebo 0%)
dental caries 3.8% (placebo 1.9%)
NCT00687193 · Phase 2 · registry result, not featured evidence
10 mg
hyperlipidaemia 11.3% (placebo 0%)
hypercholesterolaemia 5.7% (placebo 0%)
nasopharyngitis 5.7% (placebo 11.5%)
NCT00687193 · Phase 2 · registry result, not featured evidence
15 mg
nasopharyngitis 14.8% (placebo 11.5%)
low density lipoprotein increased 11.1% (placebo 0%)
constipation 5.6% (placebo 3.8%)
NCT00687193 · Phase 2 · registry result, not featured evidence
3 mg
nasopharyngitis 7.5% (placebo 11.5%)
headache 5.7% (placebo 1.9%)
hypercholesterolaemia 3.8% (placebo 0%)
NCT00687193 · Phase 2 · registry result, not featured evidence
1 mg
nasopharyngitis 11.3% (placebo 11.5%)
fall 5.7% (placebo 0%)
abdominal discomfort 3.8% (placebo 1.9%)
NCT00687193 · Phase 2 · registry result, not featured evidence
5 mg
urinary tract infection 10.2% (placebo 5.9%)
diarrhoea 6.1% (placebo 0%)
bronchitis 4.1% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
10 mg
headache 9.8% (placebo 2.9%)
diarrhoea 6.6% (placebo 0%)
hypertension 4.9% (placebo 2.9%)
NCT00550446 · Phase 2 · registry result, not featured evidence
15 mg
urinary tract infection 10.5% (placebo 5.9%)
bronchitis 7% (placebo 0%)
back pain 5.3% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
3 mg
diarrhoea 8.8% (placebo 0%)
back pain 5.9% (placebo 0%)
bronchitis 5.9% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
1 mg
urinary tract infection 8.1% (placebo 5.9%)
diarrhoea 5.4% (placebo 0%)
dizziness 5.4% (placebo 2.9%)
NCT00550446 · Phase 2 · registry result, not featured evidence
5 mg
alanine aminotransferase increased 22.2% (placebo 3.6%)
aspartate aminotransferase increased 14.8% (placebo 3.6%)
stomach discomfort 11.1% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 15.4% (placebo 14.3%)
alanine aminotransferase increased 7.7% (placebo 3.6%)
blood triglycerides increased 7.7% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
3 mg
blood cholesterol increased 11.1% (placebo 0%)
alanine aminotransferase increased 7.4% (placebo 3.6%)
aspartate aminotransferase increased 7.4% (placebo 3.6%)
NCT00603512 · Phase 2 · registry result, not featured evidence
1 mg
nasopharyngitis 10.7% (placebo 14.3%)
headache 7.1% (placebo 3.6%)
stomatitis 7.1% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
5 mg
diarrhoea 12.7% (placebo 3.9%)
nasopharyngitis 7% (placebo 5.9%)
upper respiratory tract infection 7% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
10 mg
cough 8.1% (placebo 0%)
influenza 6.8% (placebo 2%)
nausea 6.8% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
20 mg
headache 13.4% (placebo 2%)
urinary tract infection 9% (placebo 0%)
nasopharyngitis 6% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
20 mg to 5 mg (R)
headache 23.1% (placebo 2%)
upper respiratory tract infection 15.4% (placebo 2%)
abdominal pain upper 7.7% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
15 mg
nasopharyngitis 8% (placebo 5.9%)
alanine aminotransferase increased 6.7% (placebo 2%)
aspartate aminotransferase increased 6.7% (placebo 0%)
NCT00413660 · Phase 2 · registry result, not featured evidence
3 mg
nausea 5.5% (placebo 2%)
pharyngitis 5.5% (placebo 3.9%)
abdominal pain upper 3.6% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
3 mg to 5 mg (R)
upper respiratory tract infection 23.1% (placebo 2%)
arthralgia 15.4% (placebo 0%)
headache 15.4% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
1 mg
diarrhoea 14.3% (placebo 3.9%)
abdominal pain upper 4.1% (placebo 5.9%)
headache 4.1% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
1 mg to 5 mg (R)
gastritis 9.5% (placebo 0%)
nasopharyngitis 9.5% (placebo 5.9%)
oral herpes 9.5% (placebo 0%)
NCT00413660 · Phase 2 · registry result, not featured evidence
5 mg BID
headache 16.4% (placebo 9.2%)
abdominal pain upper 6.6% (placebo 0%)
nausea 6.6% (placebo 4.6%)
NCT00147498 · Phase 2 · registry result, not featured evidence
30 mg BID
headache 24.6% (placebo 9.2%)
leukopenia 10.1% (placebo 1.5%)
nausea 8.7% (placebo 4.6%)
NCT00147498 · Phase 2 · registry result, not featured evidence
15 mg BID
headache 11.6% (placebo 9.2%)
dizziness 5.8% (placebo 1.5%)
hypercholesterolaemia 5.8% (placebo 0%)
NCT00147498 · Phase 2 · registry result, not featured evidence
nasopharyngitis 8.2% (placebo 5.9%)
headache 6.2% (placebo 2%)
nausea 5.2% (placebo 3.9%)
NCT01484561 · Phase 1 · registry result, not featured evidence
nausea 16.7%
arthralgia 8.3%
back pain 8.3%
NCT01745055 · Phase 1 · registry result, not featured evidence
anemia 16.7%
arthralgia 8.3%
back pain 8.3%
NCT01745055 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eTrial phases differ: Phase 3 versus Phase 2.
  6. fAssessment timepoints differ: 312 weeks versus 24 weeks.
  7. gTrial phases differ: Phase 4 versus Phase 3.
  8. hAssessment timepoints differ: 48 weeks versus 24 weeks.
  9. iTrial phases differ: Phase 2 versus Phase 3.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

filgotinib

Tender Joint Count -13 vs -8 placebo count @ 4wk200 mg
absolute change · count
NCT02873936 · Phase 3
show 35 more results
-18 vs -12 placebo count @ 12wk200 mg
NCT02873936 · Phase 3
-22 vs -17 placebo count @ 24wk200 mg
NCT02873936 · Phase 3
-9 vs -5 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-13 vs -8 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-18 vs -15 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-22 vs -19 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-23 vs -21 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-23 vs -21 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-8 vs -5 placebo count @ 2wk200 mg
NCT02889796 · Phase 3
-11 vs -8 placebo count @ 4wk200 mg
NCT02889796 · Phase 3
-17 vs -13 placebo count @ 12wk200 mg
NCT02889796 · Phase 3
-20 vs -17 placebo count @ 24wk200 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 36wk200 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 52wk200 mg
NCT02889796 · Phase 3
-11 vs -8 placebo count @ 4wk100 mg
NCT02873936 · Phase 3
-16 vs -12 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-19 vs -17 placebo count @ 24wk100 mg
NCT02873936 · Phase 3
-7 vs -5 placebo count @ 2wk100 mg
NCT02889796 · Phase 3
-10 vs -8 placebo count @ 4wk100 mg
NCT02889796 · Phase 3
-15 vs -13 placebo count @ 12wk100 mg
NCT02889796 · Phase 3
-19 vs -17 placebo count @ 24wk100 mg
NCT02889796 · Phase 3
-20 vs -21 placebo count @ 36wk100 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 52wk100 mg
NCT02889796 · Phase 3
-9 vs -5 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -8 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-18 vs -15 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-20 vs -19 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-22 vs -21 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-8 vs -5 MTX count @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-12 vs -8 MTX count @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-17 vs -15 MTX count @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-20 vs -19 MTX count @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Swollen Joint Count -10 vs -7 placebo count @ 4wk200 mg
absolute change · count
NCT02873936 · Phase 3
show 35 more results
-12 vs -8 placebo count @ 12wk200 mg
NCT02873936 · Phase 3
-14 vs -12 placebo count @ 24wk200 mg
NCT02873936 · Phase 3
-7 vs -4 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-9 vs -6 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-13 vs -11 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-15 vs -13 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-15 vs -14 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-16 vs -14 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-6 vs -5 placebo count @ 2wk200 mg
NCT02889796 · Phase 3
-8 vs -6 placebo count @ 4wk200 mg
NCT02889796 · Phase 3
-11 vs -10 placebo count @ 12wk200 mg
NCT02889796 · Phase 3
-13 vs -12 placebo count @ 24wk200 mg
NCT02889796 · Phase 3
-14 vs -14 placebo count @ 36wk200 mg
NCT02889796 · Phase 3
-14 vs -14 placebo count @ 52wk200 mg
NCT02889796 · Phase 3
-7 vs -7 placebo count @ 4wk100 mg
NCT02873936 · Phase 3
-10 vs -8 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-13 vs -12 placebo count @ 24wk100 mg
NCT02873936 · Phase 3
-5 vs -5 placebo count @ 2wk100 mg
NCT02889796 · Phase 3
-8 vs -6 placebo count @ 4wk100 mg
NCT02889796 · Phase 3
-11 vs -10 placebo count @ 12wk100 mg
NCT02889796 · Phase 3
-13 vs -12 placebo count @ 24wk100 mg
NCT02889796 · Phase 3
-13 vs -14 placebo count @ 36wk100 mg
NCT02889796 · Phase 3
-13 vs -14 placebo count @ 52wk100 mg
NCT02889796 · Phase 3
-7 vs -4 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-9 vs -6 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -11 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-14 vs -13 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-15 vs -14 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-6 vs -4 MTX count @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-9 vs -6 MTX count @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-12 vs -11 MTX count @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -13 MTX count @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 52wk100 mg
NCT02886728 · Phase 3 · combination
HAQ Improvement 60.4% (n=147) vs 40.3% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 23 more results
66.7% (n=147) vs 44.4% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
68.8% (n=147) vs 35.4% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
53.9% (n=210) vs 42.2% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
68.6% (n=210) vs 53.9% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
74% (n=210) vs 69.8% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
77% (n=210) vs 73.9% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
73.5% (n=210) vs 67.1% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
70.6% (n=210) vs 61% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
54.7% (n=153) vs 40.3% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
66.2% (n=153) vs 44.4% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
54.1% (n=153) vs 35.4% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
61.9% (n=416) vs 42.2% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
72.4% (n=416) vs 53.9% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
80.3% (n=416) vs 69.8% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
76.6% (n=416) vs 73.9% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
73.4% (n=416) vs 67.1% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
70.9% (n=416) vs 61% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
58.5% (n=207) vs 42.2% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
61% (n=207) vs 53.9% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
74.5% (n=207) vs 69.8% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
78.5% (n=207) vs 73.9% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
76.5% (n=207) vs 67.1% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
71.5% (n=207) vs 61% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
ACR-N 26.9% (n=147) vs 13.7% (n=148) placebo @ 4wk200 mg
absolute value · percentage points
NCT02873936 · Phase 3
show 17 more results
43.4% (n=147) vs 19.7% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
53.5% (n=147) vs 31.9% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
18.3% (n=475) vs 8% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
27.4% (n=475) vs 15.1% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
46.8% (n=475) vs 28.1% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
58.8% (n=475) vs 42.6% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
62.5% (n=475) vs 63.2% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
66% (n=475) vs 63.8% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
25.8% (n=153) vs 13.7% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
37.1% (n=153) vs 19.7% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
45.5% (n=153) vs 31.9% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
14% (n=480) vs 8% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
23% (n=480) vs 15.1% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
40.6% (n=480) vs 28.1% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
55.4% (n=480) vs 42.6% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
59.1% (n=480) vs 63.2% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
63.1% (n=480) vs 63.8% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
EULAR Good 21.8% (n=147) vs 8.8% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
Week 4 · Good Response
NCT02873936 · Phase 3 · converted to % from 32 Participants as posted
show 6 more results
30% (n=210) vs 10.8% (n=416) MTX @ 4wk*200 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 63 Participants as posted
24.6% (n=475) vs 7.8% (n=475) placebo @ 4wk*200 mg
Week 4 · Good Response
NCT02889796 · Phase 3 · converted to % from 117 Participants as posted
22.2% (n=153) vs 8.8% (n=148) placebo @ 4wk*100 mg
Week 4 · Good Response
NCT02873936 · Phase 3 · converted to % from 34 Participants as posted
17.9% (n=480) vs 7.8% (n=475) placebo @ 4wk*100 mg
Week 4 · Good Response
NCT02889796 · Phase 3 · converted to % from 86 Participants as posted
28.8% (n=416) vs 10.8% (n=416) MTX @ 4wk*200 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 120 Participants as posted
21.7% (n=207) vs 10.8% (n=416) MTX @ 4wk*100 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 45 Participants as posted
EULAR Moderate 50.3% (n=147) vs 35.8% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
Week 4 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 74 Participants as posted
show 6 more results
46.2% (n=210) vs 38.7% (n=416) MTX @ 4wk*200 mg
Week 4 · Moderate Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 97 Participants as posted
48.6% (n=475) vs 39.8% (n=475) placebo @ 4wk*200 mg
Week 4 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 231 Participants as posted
42.5% (n=153) vs 35.8% (n=148) placebo @ 4wk*100 mg
Week 4 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 65 Participants as posted
50.4% (n=480) vs 39.8% (n=475) placebo @ 4wk*100 mg
Week 4 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 242 Participants as posted
49.5% (n=416) vs 38.7% (n=416) MTX @ 4wk*200 mg
Week 4 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 206 Participants as posted
50.2% (n=207) vs 38.7% (n=416) MTX @ 4wk*100 mg
Week 4 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 104 Participants as posted
EULAR Good 39.5% (n=147) vs 15.5% (n=148) placebo @ 12wk200 mg
responder rate · % of participants
Week 12 · Good Response
NCT02873936 · Phase 3 · converted to % from 58 Participants as posted
show 6 more results
46.7% (n=210) vs 27.9% (n=416) MTX @ 12wk*200 mg
Week 12 · Good Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 98 Participants as posted
49.3% (n=475) vs 22.3% (n=475) placebo @ 12wk*200 mg
Week 12 · Good Response
NCT02889796 · Phase 3 · converted to % from 234 Participants as posted
36.6% (n=153) vs 15.5% (n=148) placebo @ 12wk*100 mg
Week 12 · Good Response
NCT02873936 · Phase 3 · converted to % from 56 Participants as posted
36.9% (n=480) vs 22.3% (n=475) placebo @ 12wk*100 mg
Week 12 · Good Response
NCT02889796 · Phase 3 · converted to % from 177 Participants as posted
55.3% (n=416) vs 27.9% (n=416) MTX @ 12wk*200 mg
Week 12 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 230 Participants as posted
48.3% (n=207) vs 27.9% (n=416) MTX @ 12wk*100 mg
Week 12 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 100 Participants as posted
EULAR Moderate 44.2% (n=147) vs 34.5% (n=148) placebo @ 12wk200 mg
responder rate · % of participants
Week 12 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 65 Participants as posted
show 6 more results
36.7% (n=210) vs 45.7% (n=416) MTX @ 12wk*200 mg
Week 12 · Moderate Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 77 Participants as posted
39.6% (n=475) vs 47.2% (n=475) placebo @ 12wk*200 mg
Week 12 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 188 Participants as posted
37.9% (n=153) vs 34.5% (n=148) placebo @ 12wk*100 mg
Week 12 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 58 Participants as posted
46.9% (n=480) vs 47.2% (n=475) placebo @ 12wk*100 mg
Week 12 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 225 Participants as posted
31.3% (n=416) vs 45.7% (n=416) MTX @ 12wk*200 mg
Week 12 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 130 Participants as posted
38.2% (n=207) vs 45.7% (n=416) MTX @ 12wk*100 mg
Week 12 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 79 Participants as posted
EULAR Good 47.6% (n=147) vs 20.9% (n=148) placebo @ 24wk200 mg
responder rate · % of participants
Week 24 · Good Response
NCT02873936 · Phase 3 · converted to % from 70 Participants as posted
show 6 more results
60% (n=210) vs 44.7% (n=416) MTX @ 24wk*200 mg
Week 24 · Good Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 126 Participants as posted
59.8% (n=475) vs 32.4% (n=475) placebo @ 24wk*200 mg
Week 24 · Good Response
NCT02889796 · Phase 3 · converted to % from 284 Participants as posted
37.9% (n=153) vs 20.9% (n=148) placebo @ 24wk*100 mg
Week 24 · Good Response
NCT02873936 · Phase 3 · converted to % from 58 Participants as posted
52.1% (n=480) vs 32.4% (n=475) placebo @ 24wk*100 mg
Week 24 · Good Response
NCT02889796 · Phase 3 · converted to % from 250 Participants as posted
68% (n=416) vs 44.7% (n=416) MTX @ 24wk*200 mg
Week 24 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 283 Participants as posted
61.4% (n=207) vs 44.7% (n=416) MTX @ 24wk*100 mg
Week 24 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 127 Participants as posted
EULAR Moderate 29.3% (n=147) vs 30.4% (n=148) placebo @ 24wk200 mg
responder rate · % of participants
Week 24 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 43 Participants as posted
show 6 more results
24.8% (n=210) vs 36.8% (n=416) MTX @ 24wk*200 mg
Week 24 · Moderate Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
26.1% (n=475) vs 35.8% (n=475) placebo @ 24wk*200 mg
Week 24 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 124 Participants as posted
30.7% (n=153) vs 30.4% (n=148) placebo @ 24wk*100 mg
Week 24 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 47 Participants as posted
32.5% (n=480) vs 35.8% (n=475) placebo @ 24wk*100 mg
Week 24 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 156 Participants as posted
19.7% (n=416) vs 36.8% (n=416) MTX @ 24wk*200 mg
Week 24 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 82 Participants as posted
26.6% (n=207) vs 36.8% (n=416) MTX @ 24wk*100 mg
Week 24 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 55 Participants as posted
EQ-5D-VAS 59 vs 52 placebo score @ 4wk200 mg
absolute value · score
NCT02873936 · Phase 3
show 30 more results
66 vs 58 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
70 vs 62 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
62 vs 56 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
66 vs 64 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
68 vs 69 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
69 vs 68 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
71 vs 71 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
59 vs 56 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
66 vs 59 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
67 vs 64 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
69 vs 73 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
72 vs 73 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
60 vs 52 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
65 vs 58 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
69 vs 62 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
59 vs 56 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
66 vs 59 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
69 vs 64 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
72 vs 73 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
73 vs 73 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
65 vs 56 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
69 vs 64 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
73 vs 69 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
73 vs 68 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
75 vs 71 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
61 vs 56 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
67 vs 64 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
72 vs 69 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
71 vs 68 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
72 vs 71 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
EQ-5D VAS 10 vs 6 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 30 more results
17 vs 12 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
22 vs 17 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
11 vs 7 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
15 vs 14 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
17 vs 19 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
18 vs 19 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
20 vs 22 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
11 vs 10 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
18 vs 13 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
19 vs 18 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
21 vs 28 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
25 vs 29 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
14 vs 6 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
19 vs 12 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
25 vs 17 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
10 vs 10 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
17 vs 13 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
21 vs 18 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
23 vs 28 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
24 vs 29 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
16 vs 7 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
19 vs 14 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
24 vs 19 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
23 vs 19 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
26 vs 22 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
10 vs 7 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
17 vs 14 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
21 vs 19 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
21 vs 19 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
22 vs 22 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination

+ 237 further endpoints in the CSV export.

tofacitinib

DAS28-ESR Remission 6.11% (n=229) vs 4.81% (n=104) placebo @ 12wk5 mg
responder rate · % of participants
NCT00814307 · Phase 3
show 35 more results
9.13% (n=263) vs 2.7% (n=148) placebo @ 24wk5 mg
NCT00856544 · Phase 3
6.21% (n=177) vs 1.09% (n=92) placebo @ 24wk5 mg twice daily
NCT00853385 · Phase 3
7.17% (n=265) vs 1.55% (n=129) placebo @ 24wk5 mg
NCT00847613 · Phase 3
1.55% (n=265) vs 0% (n=129) placebo @ 4.33wk5 mg
NCT00847613 · Phase 3
5.28% (n=265) vs 1.55% (n=129) placebo @ 13wk5 mg
NCT00847613 · Phase 3
7.17% (n=265) vs 1.55% (n=129) placebo @ 26wk5 mg
NCT00847613 · Phase 3
6.72% (n=119) vs 1.67% (n=120) placebo @ 12wk5 mg
NCT00960440 · Phase 3
2.07% (n=342) vs 0% (n=171) MTX @ 4.33wk5 mg BID
NCT01039688 · Phase 3
9.06% (n=342) vs 2.35% (n=171) MTX @ 8.67wk5 mg BID
NCT01039688 · Phase 3
13.74% (n=342) vs 4.68% (n=171) MTX @ 13wk5 mg BID
NCT01039688 · Phase 3
14.62% (n=342) vs 7.6% (n=171) MTX @ 26wk5 mg BID
NCT01039688 · Phase 3
16.37% (n=342) vs 9.94% (n=171) MTX @ 39wk5 mg BID
NCT01039688 · Phase 3
18.71% (n=342) vs 11.7% (n=171) MTX @ 52wk5 mg BID
NCT01039688 · Phase 3
16.37% (n=342) vs 12.87% (n=171) MTX @ 65wk5 mg BID
NCT01039688 · Phase 3
16.96% (n=342) vs 11.11% (n=171) MTX @ 78wk5 mg BID
NCT01039688 · Phase 3
18.42% (n=342) vs 8.77% (n=171) MTX @ 91wk5 mg BID
NCT01039688 · Phase 3
20.76% (n=342) vs 9.94% (n=171) MTX @ 104wk5 mg BID
NCT01039688 · Phase 3
10.05% (n=219) vs 4.81% (n=104) placebo @ 12wk10 mg
NCT00814307 · Phase 3
13.33% (n=270) vs 2.7% (n=148) placebo @ 24wk10 mg
NCT00856544 · Phase 3
12.5% (n=176) vs 1.09% (n=92) placebo @ 24wk10 mg twice daily
NCT00853385 · Phase 3
15.95% (n=257) vs 1.55% (n=129) placebo @ 24wk10 mg
NCT00847613 · Phase 3
2.8% (n=257) vs 0% (n=129) placebo @ 4.33wk10 mg
NCT00847613 · Phase 3
11.28% (n=257) vs 1.55% (n=129) placebo @ 13wk10 mg
NCT00847613 · Phase 3
15.95% (n=257) vs 1.55% (n=129) placebo @ 26wk10 mg
NCT00847613 · Phase 3
11.2% (n=125) vs 1.67% (n=120) placebo @ 12wk10 mg
NCT00960440 · Phase 3
5.69% (n=372) vs 0% (n=171) MTX @ 4.33wk10 mg BID
NCT01039688 · Phase 3
12.9% (n=372) vs 2.35% (n=171) MTX @ 8.67wk10 mg BID
NCT01039688 · Phase 3
17.47% (n=372) vs 4.68% (n=171) MTX @ 13wk10 mg BID
NCT01039688 · Phase 3
21.77% (n=372) vs 7.6% (n=171) MTX @ 26wk10 mg BID
NCT01039688 · Phase 3
23.66% (n=372) vs 9.94% (n=171) MTX @ 39wk10 mg BID
NCT01039688 · Phase 3
23.39% (n=372) vs 11.7% (n=171) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
24.19% (n=372) vs 12.87% (n=171) MTX @ 65wk10 mg BID
NCT01039688 · Phase 3
19.89% (n=372) vs 11.11% (n=171) MTX @ 78wk10 mg BID
NCT01039688 · Phase 3
21.42% (n=372) vs 8.77% (n=171) MTX @ 91wk10 mg BID
NCT01039688 · Phase 3
22.31% (n=372) vs 9.94% (n=171) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
DAS28-ESR 4.78 vs 5.54 placebo score @ 13wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 113 more results
4.41 vs 5.32 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
4.14 vs 4.34 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
5.23 vs 5.93 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
4.64 vs 5.6 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
4.4 vs 4.61 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
4 vs 4.2 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
3.85 vs 3.95 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
5.12 vs 5.83 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
4.58 vs 5.57 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
4.34 vs 4.81 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
4.58 vs 5.56 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
5.18 vs 5.84 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
4.54 vs 5.35 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
4.21 vs 4.98 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
4.05 vs 4.61 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
3.84 vs 4.27 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
3.69 vs 4.23 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
3.59 vs 4.17 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
3.51 vs 4.05 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
3.49 vs 4.09 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
3.43 vs 3.99 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
5.61 vs 6.04 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.23 vs 5.7 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.9 vs 5.64 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.7 vs 5.56 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.5 vs 5.54 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.37 vs 5.39 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.25 vs 4.53 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.47 vs 4.47 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.33 vs 4.51 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.09 vs 5.46 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.48 vs 5.34 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.03 vs 5.49 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.49 vs 5.22 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.13 vs 5.07 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.55 vs 5.54 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
4.2 vs 5.32 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
3.84 vs 4.34 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
5.14 vs 5.93 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
4.66 vs 5.6 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
4.21 vs 4.61 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
4.08 vs 4.2 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
3.88 vs 3.95 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
4.84 vs 5.83 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
4.19 vs 5.57 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
3.9 vs 4.81 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
4.26 vs 5.56 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
4.7 vs 5.84 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
4.17 vs 5.35 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
3.94 vs 4.98 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
3.62 vs 4.61 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
3.53 vs 4.27 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
3.37 vs 4.23 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
3.32 vs 4.17 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
3.33 vs 4.05 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
3.33 vs 4.09 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
3.29 vs 3.99 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
5.2 vs 6.04 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.69 vs 5.7 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.33 vs 5.64 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.22 vs 5.56 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.93 vs 5.54 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.95 vs 5.39 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.86 vs 4.53 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.67 vs 4.47 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.62 vs 4.51 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.88 vs 5.46 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.28 vs 5.34 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.72 vs 5.49 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.13 vs 5.22 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.83 vs 5.07 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.2 vs 6.04 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.46 vs 5.7 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.02 vs 5.64 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8 vs 5.56 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.54 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.77 vs 5.39 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.63 vs 4.53 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.54 vs 4.47 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.61 vs 4.51 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.57 vs 6.04 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.1 vs 5.7 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.91 vs 5.64 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.89 vs 5.56 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.81 vs 5.54 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.78 vs 5.39 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.96 vs 4.53 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.08 vs 4.47 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.72 vs 4.51 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.33 vs 5.46 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.03 vs 5.34 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.54 vs 5.49 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4 vs 5.22 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.9 vs 5.07 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.92 vs 6.04 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.73 vs 5.7 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.36 vs 5.64 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.31 vs 5.56 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.22 vs 5.54 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.41 vs 5.39 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.39 vs 4.53 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.76 vs 4.47 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.87 vs 4.51 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.42 vs 5.46 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.29 vs 5.34 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5 vs 5.49 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.37 vs 5.22 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.07 vs 5.07 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
6.55 vs 6.32 placebo score @ 0.14wk
NCT00976599 · Phase 2 · registry result, not featured evidence
4.9 vs 6.03 placebo score @ 4wk
NCT00976599 · Phase 2 · registry result, not featured evidence
6.6 vs 6.44 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
4.33 vs 4.26 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.84 vs 3.81 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
DAS28-ESR 4.33 score @ 24wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 9 more results
3.82 score @ 48wk5 mg
NCT00856544 · Phase 3
4.12 score @ 39wk5 mg
NCT00847613 · Phase 3
4.09 score @ 52wk5 mg
NCT00847613 · Phase 3
3.99 score @ 24wk5 mg
NCT00960440 · Phase 3
4.01 score @ 24wk10 mg
NCT00814307 · Phase 3
3.5 score @ 48wk10 mg
NCT00856544 · Phase 3
3.84 score @ 39wk10 mg
NCT00847613 · Phase 3
3.79 score @ 52wk10 mg
NCT00847613 · Phase 3
3.7 score @ 24wk10 mg
NCT00960440 · Phase 3
DAS28-CRP 4.79 vs 5.3 placebo score @ 2wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 203 more results
4.41 vs 4.98 placebo score @ 4.33wk5 mg
NCT00814307 · Phase 3
4.02 vs 4.85 placebo score @ 8.67wk5 mg
NCT00814307 · Phase 3
3.89 vs 4.68 placebo score @ 13wk5 mg
NCT00814307 · Phase 3
4.41 vs 4.92 placebo score @ 2wk5 mg
NCT00856544 · Phase 3
4.08 vs 4.68 placebo score @ 4.33wk5 mg
NCT00856544 · Phase 3
3.7 vs 4.59 placebo score @ 8.67wk5 mg
NCT00856544 · Phase 3
3.62 vs 4.51 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
3.46 vs 3.92 placebo score @ 19.5wk5 mg
NCT00856544 · Phase 3
3.39 vs 3.6 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
4.26 vs 5.09 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
3.78 vs 4.83 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
3.51 vs 3.85 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
3.13 vs 3.46 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
3.05 vs 3.18 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
4.04 vs 4.73 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
3.62 vs 4.54 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
3.33 vs 3.79 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
4.46 vs 5.1 placebo score @ 2wk5 mg
NCT00960440 · Phase 3
4.14 vs 4.92 placebo score @ 4.33wk5 mg
NCT00960440 · Phase 3
3.74 vs 4.78 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
4.21 vs 4.96 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
3.67 vs 4.5 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
3.41 vs 4.14 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
3.21 vs 3.85 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
3.05 vs 3.49 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
2.92 vs 3.42 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
2.78 vs 3.38 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
2.7 vs 3.32 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
2.67 vs 3.33 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
2.65 vs 3.22 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
4.63 vs 5.24 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.36 vs 5.01 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.16 vs 4.92 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.01 vs 4.84 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8 vs 4.83 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.76 vs 4.83 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.55 vs 3.93 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.68 vs 3.97 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.64 vs 3.96 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.09 vs 4.61 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.46 vs 4.43 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.21 vs 4.56 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.77 vs 4.31 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.55 vs 4.15 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.26 vs 4.91 placebo score @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.03 vs 4.6 placebo score @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.68 vs 4.35 placebo score @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.54 vs 4.3 placebo score @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.57 vs 4.37 placebo score @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.19 vs 3.93 placebo score @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.09 vs 3.81 placebo score @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.03 vs 3.48 placebo score @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.42 vs 5.3 placebo score @ 2wk10 mg
NCT00814307 · Phase 3
3.99 vs 4.98 placebo score @ 4.33wk10 mg
NCT00814307 · Phase 3
3.64 vs 4.85 placebo score @ 8.67wk10 mg
NCT00814307 · Phase 3
3.59 vs 4.68 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
4.18 vs 4.92 placebo score @ 2wk10 mg
NCT00856544 · Phase 3
3.83 vs 4.68 placebo score @ 4.33wk10 mg
NCT00856544 · Phase 3
3.49 vs 4.59 placebo score @ 8.67wk10 mg
NCT00856544 · Phase 3
3.44 vs 4.51 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
3.15 vs 3.92 placebo score @ 19.5wk10 mg
NCT00856544 · Phase 3
3.09 vs 3.6 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
4.21 vs 5.09 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
3.77 vs 4.83 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
3.29 vs 3.85 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
3.2 vs 3.46 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
3 vs 3.18 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
3.84 vs 4.73 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
3.29 vs 4.54 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
2.96 vs 3.79 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
4.13 vs 5.1 placebo score @ 2wk10 mg
NCT00960440 · Phase 3
3.92 vs 4.92 placebo score @ 4.33wk10 mg
NCT00960440 · Phase 3
3.45 vs 4.78 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
3.77 vs 4.96 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
3.31 vs 4.5 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
3.05 vs 4.14 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
2.76 vs 3.85 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
2.69 vs 3.49 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
2.52 vs 3.42 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
2.5 vs 3.38 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
2.47 vs 3.32 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
2.48 vs 3.33 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
2.44 vs 3.22 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
4.16 vs 5.24 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.01 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.45 vs 4.92 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.37 vs 4.84 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 4.83 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.11 vs 4.83 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 3.93 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.85 vs 3.97 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.92 vs 3.96 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.74 vs 4.61 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.25 vs 4.43 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.8 vs 4.56 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.52 vs 4.31 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.14 vs 4.15 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.18 vs 4.91 placebo score @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.66 vs 4.6 placebo score @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.59 vs 4.35 placebo score @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.61 vs 4.3 placebo score @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.4 vs 4.37 placebo score @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.34 vs 3.93 placebo score @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.81 placebo score @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.15 vs 3.48 placebo score @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.28 vs 4.91 placebo score @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.99 vs 4.6 placebo score @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.94 vs 4.35 placebo score @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.72 vs 4.3 placebo score @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.61 vs 4.37 placebo score @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.93 placebo score @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.65 vs 3.93 placebo score @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.08 vs 3.81 placebo score @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.82 vs 3.81 placebo score @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.07 vs 3.48 placebo score @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.51 vs 3.48 placebo score @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.32 vs 5.24 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.01 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.34 vs 4.92 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.13 vs 4.84 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.05 vs 4.83 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 4.83 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.92 vs 3.93 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.93 vs 3.97 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.82 vs 3.96 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.18 vs 4.91 placebo score @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.75 vs 4.6 placebo score @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.6 vs 4.35 placebo score @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.38 vs 4.3 placebo score @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.28 vs 4.37 placebo score @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.12 vs 3.93 placebo score @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
2.94 vs 3.81 placebo score @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
2.91 vs 3.48 placebo score @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.6 vs 5.24 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.16 vs 5.01 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.02 vs 4.92 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4 vs 4.84 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.92 vs 4.83 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.96 vs 4.83 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.3 vs 3.93 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.26 vs 3.97 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.11 vs 3.96 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.3 vs 4.61 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.95 vs 4.43 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.63 vs 4.56 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.03 vs 4.31 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.14 vs 4.15 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.46 vs 4.91 placebo score @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.03 vs 4.6 placebo score @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.74 vs 4.35 placebo score @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.63 vs 4.3 placebo score @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.46 vs 4.37 placebo score @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.11 vs 3.93 placebo score @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.19 vs 3.93 placebo score @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.06 vs 3.81 placebo score @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.24 vs 3.81 placebo score @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.48 placebo score @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.08 vs 3.48 placebo score @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.96 vs 5.24 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.77 vs 5.01 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.42 vs 4.92 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.52 vs 4.84 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.37 vs 4.83 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.57 vs 4.83 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.63 vs 3.93 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.94 vs 3.97 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.11 vs 3.96 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.3 vs 4.61 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.23 vs 4.43 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.96 vs 4.56 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.43 vs 4.31 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.21 vs 4.15 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.88 vs 4.91 placebo score @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.45 vs 4.6 placebo score @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.32 vs 4.35 placebo score @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.21 vs 4.3 placebo score @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.98 vs 4.37 placebo score @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.59 vs 3.93 placebo score @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.33 vs 3.93 placebo score @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.48 vs 3.81 placebo score @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.83 vs 3.81 placebo score @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.39 vs 3.48 placebo score @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.88 vs 3.48 placebo score @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
5.57 vs 5.22 placebo score @ 0.14wk
NCT00976599 · Phase 2 · registry result, not featured evidence
4.06 vs 4.91 placebo score @ 4wk
NCT00976599 · Phase 2 · registry result, not featured evidence
5.38 vs 5.23 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.44 vs 3.33 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.06 vs 2.99 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
DAS28-CRP 3.65 score @ 17.33wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 17 more results
3.54 score @ 21.67wk5 mg
NCT00814307 · Phase 3
3.48 score @ 26wk5 mg
NCT00814307 · Phase 3
3.21 score @ 39wk5 mg
NCT00856544 · Phase 3
3.08 score @ 52wk5 mg
NCT00856544 · Phase 3
3.11 score @ 39wk5 mg
NCT00847613 · Phase 3
3.07 score @ 52wk5 mg
NCT00847613 · Phase 3
3.43 score @ 19.5wk5 mg
NCT00960440 · Phase 3
3.36 score @ 26wk5 mg
NCT00960440 · Phase 3
3.26 score @ 17.33wk10 mg
NCT00814307 · Phase 3
3.12 score @ 21.67wk10 mg
NCT00814307 · Phase 3
3.11 score @ 26wk10 mg
NCT00814307 · Phase 3
2.88 score @ 39wk10 mg
NCT00856544 · Phase 3
2.81 score @ 52wk10 mg
NCT00856544 · Phase 3
2.88 score @ 39wk10 mg
NCT00847613 · Phase 3
2.75 score @ 52wk10 mg
NCT00847613 · Phase 3
3.3 score @ 19.5wk10 mg
NCT00960440 · Phase 3
3.07 score @ 26wk10 mg
NCT00960440 · Phase 3
HAQ-DI 1.27 vs 1.43 placebo score @ 2wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 216 more results
1.18 vs 1.4 placebo score @ 4.33wk5 mg
NCT00814307 · Phase 3
1.05 vs 1.4 placebo score @ 8.67wk5 mg
NCT00814307 · Phase 3
1.05 vs 1.35 placebo score @ 13wk5 mg
NCT00814307 · Phase 3
1.24 vs 1.28 placebo score @ 2wk5 mg
NCT00856544 · Phase 3
1.12 vs 1.2 placebo score @ 4.33wk5 mg
NCT00856544 · Phase 3
1.03 vs 1.2 placebo score @ 8.67wk5 mg
NCT00856544 · Phase 3
0.98 vs 1.16 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
0.97 vs 0.95 placebo score @ 19.5wk5 mg
NCT00856544 · Phase 3
0.91 vs 0.93 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
1.15 vs 1.32 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
1 vs 1.25 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
0.92 vs 1.15 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
0.86 vs 0.97 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
0.83 vs 0.9 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
1.16 vs 1.25 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
1 vs 1.19 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
0.94 vs 1.09 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
1.38 vs 1.49 placebo score @ 2wk5 mg
NCT00960440 · Phase 3
1.37 vs 1.38 placebo score @ 4.33wk5 mg
NCT00960440 · Phase 3
1.2 vs 1.44 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
1.05 vs 1.3 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
0.89 vs 1.17 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
0.78 vs 1.03 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
0.69 vs 0.92 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
0.66 vs 0.83 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
0.64 vs 0.79 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
0.59 vs 0.83 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
0.58 vs 0.74 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
0.59 vs 0.76 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
0.58 vs 0.77 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
1.22 vs 1.49 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.14 vs 1.38 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.14 vs 1.31 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.99 vs 1.24 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.94 vs 1.24 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.94 vs 1.24 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.91 vs 1.28 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.96 vs 1.3 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.95 vs 1.2 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.25 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.88 vs 1.18 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.79 vs 1.07 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.72 vs 1.21 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.56 vs 1.13 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.2 vs 1.15 placebo score @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.13 vs 1.14 placebo score @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.03 vs 1.07 placebo score @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.06 vs 1.05 placebo score @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.94 vs 1.08 placebo score @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 0.8 placebo score @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.78 vs 0.73 placebo score @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.78 vs 0.74 placebo score @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.46 vs 1.63 placebo score @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.32 vs 1.53 placebo score @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.17 vs 1.54 placebo score @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.12 vs 1.47 placebo score @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.3 vs 1.52 placebo score @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.21 vs 1.43 placebo score @ 2wk10 mg
NCT00814307 · Phase 3
1.09 vs 1.4 placebo score @ 4.33wk10 mg
NCT00814307 · Phase 3
0.97 vs 1.4 placebo score @ 8.67wk10 mg
NCT00814307 · Phase 3
0.97 vs 1.35 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
1.14 vs 1.28 placebo score @ 2wk10 mg
NCT00856544 · Phase 3
1.01 vs 1.2 placebo score @ 4.33wk10 mg
NCT00856544 · Phase 3
0.93 vs 1.2 placebo score @ 8.67wk10 mg
NCT00856544 · Phase 3
0.88 vs 1.16 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
0.84 vs 0.95 placebo score @ 19.5wk10 mg
NCT00856544 · Phase 3
0.81 vs 0.93 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
1.11 vs 1.32 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
0.94 vs 1.25 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
0.89 vs 1.15 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
0.85 vs 0.97 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
0.81 vs 0.9 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
1.02 vs 1.25 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
0.84 vs 1.19 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
0.79 vs 1.09 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
1.28 vs 1.49 placebo score @ 2wk10 mg
NCT00960440 · Phase 3
1.19 vs 1.38 placebo score @ 4.33wk10 mg
NCT00960440 · Phase 3
1.1 vs 1.44 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
0.89 vs 1.3 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
0.74 vs 1.17 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
0.67 vs 1.03 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
0.57 vs 0.92 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
0.56 vs 0.83 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
0.51 vs 0.79 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
0.51 vs 0.83 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
0.48 vs 0.74 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
0.49 vs 0.76 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
0.48 vs 0.77 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
1.22 vs 1.49 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.04 vs 1.38 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1 vs 1.31 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.97 vs 1.24 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.86 vs 1.24 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.24 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.85 vs 1.28 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.8 vs 1.3 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.2 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.85 vs 1.25 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.79 vs 1.18 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.77 vs 1.07 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.64 vs 1.21 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.59 vs 1.13 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.16 vs 1.15 placebo score @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.08 vs 1.14 placebo score @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.02 vs 1.07 placebo score @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.89 vs 1.05 placebo score @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.95 vs 1.08 placebo score @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.91 vs 0.8 placebo score @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.84 vs 0.73 placebo score @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.85 vs 0.74 placebo score @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.19 vs 1.63 placebo score @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.06 vs 1.53 placebo score @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.92 vs 1.54 placebo score @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.86 vs 1.47 placebo score @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.92 vs 1.52 placebo score @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.23 vs 1.15 placebo score @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.14 vs 1.14 placebo score @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 1.07 placebo score @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.98 vs 1.05 placebo score @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.9 vs 1.08 placebo score @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.81 vs 0.8 placebo score @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.36 vs 0.8 placebo score @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.75 vs 0.73 placebo score @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.42 vs 0.73 placebo score @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.72 vs 0.74 placebo score @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.34 vs 0.74 placebo score @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.26 vs 1.49 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.08 vs 1.38 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.93 vs 1.31 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.86 vs 1.24 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.24 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.78 vs 1.24 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.73 vs 1.28 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.71 vs 1.3 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.79 vs 1.2 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.15 vs 1.15 placebo score @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.12 vs 1.14 placebo score @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 1.07 placebo score @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.98 vs 1.05 placebo score @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.96 vs 1.08 placebo score @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.97 vs 0.8 placebo score @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 0.73 placebo score @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.88 vs 0.74 placebo score @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.37 vs 1.63 placebo score @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.17 vs 1.53 placebo score @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.07 vs 1.54 placebo score @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.95 vs 1.47 placebo score @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.06 vs 1.52 placebo score @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.28 vs 1.49 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.23 vs 1.38 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.24 vs 1.31 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.12 vs 1.24 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.2 vs 1.24 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.09 vs 1.24 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.04 vs 1.28 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1 vs 1.3 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.96 vs 1.2 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.23 vs 1.25 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.12 vs 1.18 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.04 vs 1.07 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.96 vs 1.21 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.81 vs 1.13 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.14 vs 1.15 placebo score @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.03 vs 1.14 placebo score @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.96 vs 1.07 placebo score @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.93 vs 1.05 placebo score @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 1.08 placebo score @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.82 vs 0.8 placebo score @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.18 vs 0.8 placebo score @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.77 vs 0.73 placebo score @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.13 vs 0.73 placebo score @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.85 vs 0.74 placebo score @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 0.74 placebo score @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.45 vs 1.49 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.45 vs 1.38 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.3 vs 1.31 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.29 vs 1.24 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.25 vs 1.24 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.28 vs 1.24 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.02 vs 1.28 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.3 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.02 vs 1.2 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.25 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.04 vs 1.18 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.94 vs 1.07 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.8 vs 1.21 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.78 vs 1.13 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.41 vs 1.15 placebo score @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.32 vs 1.14 placebo score @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.23 vs 1.07 placebo score @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.22 vs 1.05 placebo score @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.19 vs 1.08 placebo score @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 0.8 placebo score @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.42 vs 0.8 placebo score @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.95 vs 0.73 placebo score @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.33 vs 0.73 placebo score @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.99 vs 0.74 placebo score @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.38 vs 0.74 placebo score @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.54 vs 1.46 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
0.88 vs 0.88 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
0.74 vs 0.92 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
HAQ-DI 0.97 score @ 17.33wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 96 more results
0.95 score @ 21.67wk5 mg
NCT00814307 · Phase 3
0.94 score @ 26wk5 mg
NCT00814307 · Phase 3
0.89 score @ 39wk5 mg
NCT00856544 · Phase 3
0.86 score @ 52wk5 mg
NCT00856544 · Phase 3
0.91 score @ 39wk5 mg
NCT00847613 · Phase 3
0.9 score @ 52wk5 mg
NCT00847613 · Phase 3
1.19 score @ 19.5wk5 mg
NCT00960440 · Phase 3
1.1 score @ 26wk5 mg
NCT00960440 · Phase 3
-0.57 score @ 4.33wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 8.67wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 13wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 26wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 39wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 52wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 65wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 78wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 91wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 104wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.62 score @ 117wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 130wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 143wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.63 score @ 156wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 169wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 182wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 195wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 208wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 221wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 234wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 247wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 260wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 273wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 286wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.55 score @ 299wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 312wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 325wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 338wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.55 score @ 351wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 364wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 377wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.52 score @ 390wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.52 score @ 403wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 416wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 429wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 442wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 455wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.89 score @ 468wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-1.29 score @ 481wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.13 score @ 494wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.88 score @ 17.33wk10 mg
NCT00814307 · Phase 3
0.87 score @ 21.67wk10 mg
NCT00814307 · Phase 3
0.86 score @ 26wk10 mg
NCT00814307 · Phase 3
0.71 score @ 39wk10 mg
NCT00856544 · Phase 3
0.73 score @ 52wk10 mg
NCT00856544 · Phase 3
0.75 score @ 39wk10 mg
NCT00847613 · Phase 3
0.76 score @ 52wk10 mg
NCT00847613 · Phase 3
1.1 score @ 19.5wk10 mg
NCT00960440 · Phase 3
1.02 score @ 26wk10 mg
NCT00960440 · Phase 3
-0.61 score @ 4.33wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 8.67wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 13wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 26wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 39wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 52wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 65wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 78wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 91wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 104wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 117wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 130wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 143wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 156wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 169wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 182wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 195wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 208wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.63 score @ 221wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 234wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 247wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 260wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 273wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 286wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 299wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.62 score @ 312wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 325wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 338wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 351wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.56 score @ 364wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 377wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 390wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.5 score @ 403wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.48 score @ 416wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.44 score @ 429wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.29 score @ 442wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.5 score @ 455wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.13 score @ 468wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.25 score @ 481wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
Patient Pain VAS 45.92 vs 55.61 placebo mm @ 2wk5 mg
absolute value · mm
NCT00814307 · Phase 3
show 210 more results
40.68 vs 52.47 placebo mm @ 4.33wk5 mg
NCT00814307 · Phase 3
36.39 vs 52.38 placebo mm @ 8.67wk5 mg
NCT00814307 · Phase 3
34.93 vs 49.84 placebo mm @ 13wk5 mg
NCT00814307 · Phase 3
46.81 vs 51.01 placebo mm @ 2wk5 mg
NCT00856544 · Phase 3
40.17 vs 45.69 placebo mm @ 4.33wk5 mg
NCT00856544 · Phase 3
36.4 vs 47.3 placebo mm @ 8.67wk5 mg
NCT00856544 · Phase 3
34.92 vs 46.59 placebo mm @ 13wk5 mg
NCT00856544 · Phase 3
34.43 vs 40.23 placebo mm @ 19.5wk5 mg
NCT00856544 · Phase 3
31.07 vs 34.19 placebo mm @ 26wk5 mg
NCT00856544 · Phase 3
39.71 vs 49.92 placebo mm @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
32.98 vs 48.53 placebo mm @ 13wk5 mg twice daily
NCT00853385 · Phase 3
30.4 vs 35.04 placebo mm @ 26wk5 mg twice daily
NCT00853385 · Phase 3
27.04 vs 32.7 Adalimumab mm @ 39wk5 mg twice daily
NCT00853385 · Phase 3
26.99 vs 27.94 Adalimumab mm @ 52wk5 mg twice daily
NCT00853385 · Phase 3
41.61 vs 49.22 placebo mm @ 4.33wk5 mg
NCT00847613 · Phase 3
34.47 vs 46.96 placebo mm @ 13wk5 mg
NCT00847613 · Phase 3
32.79 vs 36.76 placebo mm @ 26wk5 mg
NCT00847613 · Phase 3
36.62 vs 46.34 MTX mm @ 4.33wk5 mg BID
NCT01039688 · Phase 3
31.97 vs 39.74 MTX mm @ 8.67wk5 mg BID
NCT01039688 · Phase 3
29.41 vs 36.83 MTX mm @ 13wk5 mg BID
NCT01039688 · Phase 3
27.07 vs 30.94 MTX mm @ 26wk5 mg BID
NCT01039688 · Phase 3
26.11 vs 31.22 MTX mm @ 39wk5 mg BID
NCT01039688 · Phase 3
26.09 vs 29.91 MTX mm @ 52wk5 mg BID
NCT01039688 · Phase 3
24.25 vs 29.85 MTX mm @ 65wk5 mg BID
NCT01039688 · Phase 3
23.66 vs 27.81 MTX mm @ 78wk5 mg BID
NCT01039688 · Phase 3
23.3 vs 29.18 MTX mm @ 91wk5 mg BID
NCT01039688 · Phase 3
23.03 vs 27.52 MTX mm @ 104wk5 mg BID
NCT01039688 · Phase 3
47.1 vs 55.26 placebo mm @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.65 vs 50.89 placebo mm @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.24 vs 49.63 placebo mm @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.91 vs 47.26 placebo mm @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.67 vs 44.96 placebo mm @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
32.7 vs 43.93 placebo mm @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.39 vs 37.55 placebo mm @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.13 vs 36.95 placebo mm @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.81 vs 31.35 placebo mm @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
40.19 vs 49.36 placebo mm @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
33.19 vs 48.58 placebo mm @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
25.19 vs 49.72 placebo mm @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
22.59 vs 48.88 placebo mm @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.58 vs 44.96 placebo mm @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
44.35 vs 46.91 placebo mm @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
40.03 vs 42.02 placebo mm @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.33 vs 42.21 placebo mm @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
36.55 vs 41.34 placebo mm @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.88 vs 41.02 placebo mm @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.98 vs 30.08 placebo mm @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
25.91 vs 25.08 placebo mm @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.45 vs 27.14 placebo mm @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
51.76 vs 62.51 placebo mm @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
45.59 vs 60.65 placebo mm @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.77 vs 56.96 placebo mm @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
35.57 vs 52.75 placebo mm @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
42.44 vs 49.06 placebo mm @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
42.13 vs 55.61 placebo mm @ 2wk10 mg
NCT00814307 · Phase 3
36.86 vs 52.47 placebo mm @ 4.33wk10 mg
NCT00814307 · Phase 3
31.66 vs 52.38 placebo mm @ 8.67wk10 mg
NCT00814307 · Phase 3
31.37 vs 49.84 placebo mm @ 13wk10 mg
NCT00814307 · Phase 3
41.85 vs 51.01 placebo mm @ 2wk10 mg
NCT00856544 · Phase 3
37.08 vs 45.69 placebo mm @ 4.33wk10 mg
NCT00856544 · Phase 3
32.84 vs 47.3 placebo mm @ 8.67wk10 mg
NCT00856544 · Phase 3
32.96 vs 46.59 placebo mm @ 13wk10 mg
NCT00856544 · Phase 3
32.62 vs 40.23 placebo mm @ 19.5wk10 mg
NCT00856544 · Phase 3
29.94 vs 34.19 placebo mm @ 26wk10 mg
NCT00856544 · Phase 3
36.77 vs 49.92 placebo mm @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
31.27 vs 48.53 placebo mm @ 13wk10 mg twice daily
NCT00853385 · Phase 3
28.36 vs 35.04 placebo mm @ 26wk10 mg twice daily
NCT00853385 · Phase 3
27.99 vs 32.7 Adalimumab mm @ 39wk10 mg twice daily
NCT00853385 · Phase 3
24.55 vs 27.94 Adalimumab mm @ 52wk10 mg twice daily
NCT00853385 · Phase 3
33.91 vs 49.22 placebo mm @ 4.33wk10 mg
NCT00847613 · Phase 3
29.23 vs 46.96 placebo mm @ 13wk10 mg
NCT00847613 · Phase 3
29.05 vs 36.76 placebo mm @ 26wk10 mg
NCT00847613 · Phase 3
32.78 vs 46.34 MTX mm @ 4.33wk10 mg BID
NCT01039688 · Phase 3
30.33 vs 39.74 MTX mm @ 8.67wk10 mg BID
NCT01039688 · Phase 3
27.07 vs 36.83 MTX mm @ 13wk10 mg BID
NCT01039688 · Phase 3
24.22 vs 30.94 MTX mm @ 26wk10 mg BID
NCT01039688 · Phase 3
23.76 vs 31.22 MTX mm @ 39wk10 mg BID
NCT01039688 · Phase 3
22.64 vs 29.91 MTX mm @ 52wk10 mg BID
NCT01039688 · Phase 3
23.72 vs 29.85 MTX mm @ 65wk10 mg BID
NCT01039688 · Phase 3
22.72 vs 27.81 MTX mm @ 78wk10 mg BID
NCT01039688 · Phase 3
22.85 vs 29.18 MTX mm @ 91wk10 mg BID
NCT01039688 · Phase 3
21.09 vs 27.52 MTX mm @ 104wk10 mg BID
NCT01039688 · Phase 3
43.9 vs 55.26 placebo mm @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.28 vs 50.89 placebo mm @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.68 vs 49.63 placebo mm @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.05 vs 47.26 placebo mm @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.11 vs 44.96 placebo mm @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.14 vs 43.93 placebo mm @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.05 vs 37.55 placebo mm @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
27.43 vs 36.95 placebo mm @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
22.85 vs 31.35 placebo mm @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
37.08 vs 49.36 placebo mm @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
31.4 vs 48.58 placebo mm @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.46 vs 49.72 placebo mm @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
19.43 vs 48.88 placebo mm @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
16.9 vs 44.96 placebo mm @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
41.26 vs 46.91 placebo mm @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.34 vs 42.02 placebo mm @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.38 vs 42.21 placebo mm @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.6 vs 41.34 placebo mm @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.78 vs 41.02 placebo mm @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.33 vs 30.08 placebo mm @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.66 vs 25.08 placebo mm @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.65 vs 27.14 placebo mm @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
37.71 vs 62.51 placebo mm @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.83 vs 60.65 placebo mm @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
26.76 vs 56.96 placebo mm @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
23.39 vs 52.75 placebo mm @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
31.12 vs 49.06 placebo mm @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.57 vs 46.91 placebo mm @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
34.39 vs 42.02 placebo mm @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
33.65 vs 42.21 placebo mm @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.16 vs 41.34 placebo mm @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.09 vs 41.02 placebo mm @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
24.56 vs 30.08 placebo mm @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
51.25 vs 30.08 placebo mm @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
24.58 vs 25.08 placebo mm @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
43.92 vs 25.08 placebo mm @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
19.92 vs 27.14 placebo mm @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.33 vs 27.14 placebo mm @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
41.28 vs 55.26 placebo mm @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
32.69 vs 50.89 placebo mm @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.24 vs 49.63 placebo mm @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
26.74 vs 47.26 placebo mm @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.38 vs 44.96 placebo mm @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
27.26 vs 43.93 placebo mm @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.24 vs 37.55 placebo mm @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.21 vs 36.95 placebo mm @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
25.31 vs 31.35 placebo mm @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
37.82 vs 46.91 placebo mm @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.81 vs 42.02 placebo mm @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
32.97 vs 42.21 placebo mm @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.26 vs 41.34 placebo mm @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
31.48 vs 41.02 placebo mm @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
27.07 vs 30.08 placebo mm @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.69 vs 25.08 placebo mm @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.47 vs 27.14 placebo mm @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
46.11 vs 62.51 placebo mm @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.14 vs 60.65 placebo mm @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.42 vs 56.96 placebo mm @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
28.35 vs 52.75 placebo mm @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.62 vs 49.06 placebo mm @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
45.25 vs 55.26 placebo mm @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.91 vs 50.89 placebo mm @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
42.75 vs 49.63 placebo mm @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.21 vs 47.26 placebo mm @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.24 vs 44.96 placebo mm @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
42.3 vs 43.93 placebo mm @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.97 vs 37.55 placebo mm @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.66 vs 36.95 placebo mm @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.62 vs 31.35 placebo mm @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.5 vs 49.36 placebo mm @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
40.52 vs 48.58 placebo mm @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
34.88 vs 49.72 placebo mm @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.04 vs 48.88 placebo mm @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
27.17 vs 44.96 placebo mm @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
43.33 vs 46.91 placebo mm @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
37.83 vs 42.02 placebo mm @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
33.75 vs 42.21 placebo mm @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
28.81 vs 41.34 placebo mm @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
30.9 vs 41.02 placebo mm @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.67 vs 30.08 placebo mm @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.31 vs 30.08 placebo mm @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
26.63 vs 25.08 placebo mm @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
42.31 vs 25.08 placebo mm @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.98 vs 27.14 placebo mm @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.62 vs 27.14 placebo mm @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
53.76 vs 55.26 placebo mm @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
51.72 vs 50.89 placebo mm @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.31 vs 49.63 placebo mm @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.28 vs 47.26 placebo mm @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.7 vs 44.96 placebo mm @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.25 vs 43.93 placebo mm @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35 vs 37.55 placebo mm @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.67 vs 36.95 placebo mm @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
44.13 vs 31.35 placebo mm @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.36 vs 49.36 placebo mm @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
45.11 vs 48.58 placebo mm @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.44 vs 49.72 placebo mm @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
32.65 vs 48.88 placebo mm @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
32.19 vs 44.96 placebo mm @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
49.53 vs 46.91 placebo mm @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
45.57 vs 42.02 placebo mm @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
38.74 vs 42.21 placebo mm @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
38.97 vs 41.34 placebo mm @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
35.92 vs 41.02 placebo mm @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
27.83 vs 30.08 placebo mm @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
40.38 vs 30.08 placebo mm @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.28 vs 25.08 placebo mm @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.71 vs 25.08 placebo mm @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.53 vs 27.14 placebo mm @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.15 vs 27.14 placebo mm @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
65.66 vs 64.41 placebo mm @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
30.18 vs 31.26 placebo mm @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
25.72 vs 29.09 placebo mm @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
Patient Pain VAS 33.18 mm @ 17.33wk5 mg
absolute value · mm
No placebo or comparator arm
NCT00814307 · Phase 3
show 13 more results
32.63 mm @ 21.67wk5 mg
NCT00814307 · Phase 3
32.6 mm @ 26wk5 mg
NCT00814307 · Phase 3
30.78 mm @ 39wk5 mg
NCT00856544 · Phase 3
30.18 mm @ 52wk5 mg
NCT00856544 · Phase 3
31.59 mm @ 39wk5 mg
NCT00847613 · Phase 3
30.54 mm @ 52wk5 mg
NCT00847613 · Phase 3
29.7 mm @ 17.33wk10 mg
NCT00814307 · Phase 3
29.1 mm @ 21.67wk10 mg
NCT00814307 · Phase 3
27.89 mm @ 26wk10 mg
NCT00814307 · Phase 3
27.13 mm @ 39wk10 mg
NCT00856544 · Phase 3
25.43 mm @ 52wk10 mg
NCT00856544 · Phase 3
27.14 mm @ 39wk10 mg
NCT00847613 · Phase 3
27.45 mm @ 52wk10 mg
NCT00847613 · Phase 3
Patient Global Assessment 46.34 vs 55.95 placebo mm @ 2wk5 mg
absolute value · mm
NCT00814307 · Phase 3
show 210 more results
39.63 vs 53.23 placebo mm @ 4.33wk5 mg
NCT00814307 · Phase 3
36.29 vs 53.05 placebo mm @ 8.67wk5 mg
NCT00814307 · Phase 3
35.9 vs 50.48 placebo mm @ 13wk5 mg
NCT00814307 · Phase 3
46.59 vs 51.27 placebo mm @ 2wk5 mg
NCT00856544 · Phase 3
40.5 vs 46.25 placebo mm @ 4.33wk5 mg
NCT00856544 · Phase 3
37.18 vs 50.42 placebo mm @ 8.67wk5 mg
NCT00856544 · Phase 3
36.27 vs 47.09 placebo mm @ 13wk5 mg
NCT00856544 · Phase 3
35.92 vs 41.03 placebo mm @ 19.5wk5 mg
NCT00856544 · Phase 3
33.75 vs 35.47 placebo mm @ 26wk5 mg
NCT00856544 · Phase 3
41.85 vs 50.7 placebo mm @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
35.56 vs 49.84 placebo mm @ 13wk5 mg twice daily
NCT00853385 · Phase 3
32.79 vs 37.76 placebo mm @ 26wk5 mg twice daily
NCT00853385 · Phase 3
28.39 vs 34.38 Adalimumab mm @ 39wk5 mg twice daily
NCT00853385 · Phase 3
26.86 vs 30.33 Adalimumab mm @ 52wk5 mg twice daily
NCT00853385 · Phase 3
41.26 vs 48.3 placebo mm @ 4.33wk5 mg
NCT00847613 · Phase 3
35.07 vs 46.96 placebo mm @ 13wk5 mg
NCT00847613 · Phase 3
33.48 vs 38.87 placebo mm @ 26wk5 mg
NCT00847613 · Phase 3
38.27 vs 46.15 MTX mm @ 4.33wk5 mg BID
NCT01039688 · Phase 3
31.91 vs 41.29 MTX mm @ 8.67wk5 mg BID
NCT01039688 · Phase 3
30.36 vs 37.43 MTX mm @ 13wk5 mg BID
NCT01039688 · Phase 3
28.37 vs 32.12 MTX mm @ 26wk5 mg BID
NCT01039688 · Phase 3
26.73 vs 32.79 MTX mm @ 39wk5 mg BID
NCT01039688 · Phase 3
26.72 vs 32.4 MTX mm @ 52wk5 mg BID
NCT01039688 · Phase 3
25.19 vs 32.26 MTX mm @ 65wk5 mg BID
NCT01039688 · Phase 3
24.76 vs 29.31 MTX mm @ 78wk5 mg BID
NCT01039688 · Phase 3
24.72 vs 30.19 MTX mm @ 91wk5 mg BID
NCT01039688 · Phase 3
24.42 vs 28.81 MTX mm @ 104wk5 mg BID
NCT01039688 · Phase 3
50.58 vs 58.93 placebo mm @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
44.54 vs 51.4 placebo mm @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.07 vs 49.71 placebo mm @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.81 vs 46.74 placebo mm @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35.04 vs 47.24 placebo mm @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.52 vs 44.85 placebo mm @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.37 vs 38.65 placebo mm @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.91 vs 35.84 placebo mm @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.77 vs 32.05 placebo mm @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
42.56 vs 46.54 placebo mm @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
33.78 vs 48.42 placebo mm @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
28.93 vs 49.16 placebo mm @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
21.81 vs 49.17 placebo mm @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.13 vs 43.75 placebo mm @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.56 vs 46.33 placebo mm @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.94 vs 41.21 placebo mm @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.01 vs 43.02 placebo mm @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
36.5 vs 40.64 placebo mm @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
29.66 vs 39.85 placebo mm @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.62 vs 28.46 placebo mm @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
26.07 vs 26.22 placebo mm @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
23.64 vs 28.25 placebo mm @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
49.89 vs 61.48 placebo mm @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
46.18 vs 58.02 placebo mm @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
38.67 vs 52.55 placebo mm @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.11 vs 50.04 placebo mm @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.29 vs 50.76 placebo mm @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
41.32 vs 55.95 placebo mm @ 2wk10 mg
NCT00814307 · Phase 3
37.69 vs 53.23 placebo mm @ 4.33wk10 mg
NCT00814307 · Phase 3
32.56 vs 53.05 placebo mm @ 8.67wk10 mg
NCT00814307 · Phase 3
32.78 vs 50.48 placebo mm @ 13wk10 mg
NCT00814307 · Phase 3
42.99 vs 51.27 placebo mm @ 2wk10 mg
NCT00856544 · Phase 3
36.53 vs 46.25 placebo mm @ 4.33wk10 mg
NCT00856544 · Phase 3
33.8 vs 50.42 placebo mm @ 8.67wk10 mg
NCT00856544 · Phase 3
33.43 vs 47.09 placebo mm @ 13wk10 mg
NCT00856544 · Phase 3
34.05 vs 41.03 placebo mm @ 19.5wk10 mg
NCT00856544 · Phase 3
31.31 vs 35.47 placebo mm @ 26wk10 mg
NCT00856544 · Phase 3
36.61 vs 50.7 placebo mm @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
31.25 vs 49.84 placebo mm @ 13wk10 mg twice daily
NCT00853385 · Phase 3
29.74 vs 37.76 placebo mm @ 26wk10 mg twice daily
NCT00853385 · Phase 3
29.47 vs 34.38 Adalimumab mm @ 39wk10 mg twice daily
NCT00853385 · Phase 3
27.7 vs 30.33 Adalimumab mm @ 52wk10 mg twice daily
NCT00853385 · Phase 3
34.95 vs 48.3 placebo mm @ 4.33wk10 mg
NCT00847613 · Phase 3
29.11 vs 46.96 placebo mm @ 13wk10 mg
NCT00847613 · Phase 3
29.03 vs 38.87 placebo mm @ 26wk10 mg
NCT00847613 · Phase 3
32.63 vs 46.15 MTX mm @ 4.33wk10 mg BID
NCT01039688 · Phase 3
28.94 vs 41.29 MTX mm @ 8.67wk10 mg BID
NCT01039688 · Phase 3
28.6 vs 37.43 MTX mm @ 13wk10 mg BID
NCT01039688 · Phase 3
24.84 vs 32.12 MTX mm @ 26wk10 mg BID
NCT01039688 · Phase 3
24.98 vs 32.79 MTX mm @ 39wk10 mg BID
NCT01039688 · Phase 3
24.38 vs 32.4 MTX mm @ 52wk10 mg BID
NCT01039688 · Phase 3
23.79 vs 32.26 MTX mm @ 65wk10 mg BID
NCT01039688 · Phase 3
24.38 vs 29.31 MTX mm @ 78wk10 mg BID
NCT01039688 · Phase 3
23.86 vs 30.19 MTX mm @ 91wk10 mg BID
NCT01039688 · Phase 3
23.61 vs 28.81 MTX mm @ 104wk10 mg BID
NCT01039688 · Phase 3
41.82 vs 58.93 placebo mm @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.86 vs 51.4 placebo mm @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.63 vs 49.71 placebo mm @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.42 vs 46.74 placebo mm @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.09 vs 47.24 placebo mm @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.02 vs 44.85 placebo mm @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.71 vs 38.65 placebo mm @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.06 vs 35.84 placebo mm @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.85 vs 32.05 placebo mm @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.73 vs 46.54 placebo mm @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.44 vs 48.42 placebo mm @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.04 vs 49.16 placebo mm @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
20.39 vs 49.17 placebo mm @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
16.48 vs 43.75 placebo mm @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.32 vs 46.33 placebo mm @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.53 vs 41.21 placebo mm @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.41 vs 43.02 placebo mm @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
36.09 vs 40.64 placebo mm @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.05 vs 39.85 placebo mm @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.98 vs 28.46 placebo mm @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35 vs 26.22 placebo mm @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
29.66 vs 28.25 placebo mm @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.79 vs 61.48 placebo mm @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
32.09 vs 58.02 placebo mm @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
26.16 vs 52.55 placebo mm @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
24.52 vs 50.04 placebo mm @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.63 vs 50.76 placebo mm @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
41.8 vs 46.33 placebo mm @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.33 placebo mm @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
37.47 vs 41.21 placebo mm @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.21 placebo mm @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
34.86 vs 43.02 placebo mm @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 43.02 placebo mm @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.85 vs 40.64 placebo mm @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 40.64 placebo mm @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
30.76 vs 39.85 placebo mm @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 39.85 placebo mm @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
24.76 vs 28.46 placebo mm @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
50.67 vs 28.46 placebo mm @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.56 vs 26.22 placebo mm @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
44.42 vs 26.22 placebo mm @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
21.85 vs 28.25 placebo mm @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.83 vs 28.25 placebo mm @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
42.02 vs 58.93 placebo mm @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.73 vs 51.4 placebo mm @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.09 vs 49.71 placebo mm @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.07 vs 46.74 placebo mm @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
22.72 vs 47.24 placebo mm @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
26.39 vs 44.85 placebo mm @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.72 vs 38.65 placebo mm @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.9 vs 35.84 placebo mm @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
26.58 vs 32.05 placebo mm @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35.73 vs 46.33 placebo mm @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.76 vs 41.21 placebo mm @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.56 vs 43.02 placebo mm @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.61 vs 40.64 placebo mm @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
32.53 vs 39.85 placebo mm @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
26.59 vs 28.46 placebo mm @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.9 vs 26.22 placebo mm @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
25.07 vs 28.25 placebo mm @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
45.36 vs 61.48 placebo mm @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
41.09 vs 58.02 placebo mm @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
29.53 vs 52.55 placebo mm @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
28.82 vs 50.04 placebo mm @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.56 vs 50.76 placebo mm @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
48.49 vs 58.93 placebo mm @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
44.68 vs 51.4 placebo mm @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.52 vs 49.71 placebo mm @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.02 vs 46.74 placebo mm @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.57 vs 47.24 placebo mm @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
40.78 vs 44.85 placebo mm @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35.03 vs 38.65 placebo mm @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35.41 vs 35.84 placebo mm @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.07 vs 32.05 placebo mm @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
44.27 vs 46.54 placebo mm @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.63 vs 48.42 placebo mm @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
34.23 vs 49.16 placebo mm @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.68 vs 49.17 placebo mm @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
24.21 vs 43.75 placebo mm @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
41.96 vs 46.33 placebo mm @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.33 placebo mm @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
39.78 vs 41.21 placebo mm @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.21 placebo mm @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
36.08 vs 43.02 placebo mm @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 43.02 placebo mm @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
30.11 vs 40.64 placebo mm @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 40.64 placebo mm @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
34.42 vs 39.85 placebo mm @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 39.85 placebo mm @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.84 vs 28.46 placebo mm @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.31 vs 28.46 placebo mm @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
28.16 vs 26.22 placebo mm @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
42.08 vs 26.22 placebo mm @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.93 vs 28.25 placebo mm @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.23 vs 28.25 placebo mm @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
54.36 vs 58.93 placebo mm @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
52.96 vs 51.4 placebo mm @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.08 vs 49.71 placebo mm @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
46.57 vs 46.74 placebo mm @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.8 vs 47.24 placebo mm @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.39 vs 44.85 placebo mm @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
36.07 vs 38.65 placebo mm @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.74 vs 35.84 placebo mm @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.08 vs 32.05 placebo mm @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.89 vs 46.54 placebo mm @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
46.07 vs 48.42 placebo mm @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
44.59 vs 49.16 placebo mm @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
35.12 vs 49.17 placebo mm @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
31.42 vs 43.75 placebo mm @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
53.19 vs 46.33 placebo mm @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.33 placebo mm @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
47.87 vs 41.21 placebo mm @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.21 placebo mm @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
42.3 vs 43.02 placebo mm @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 43.02 placebo mm @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
41.06 vs 40.64 placebo mm @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 40.64 placebo mm @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
38.78 vs 39.85 placebo mm @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 39.85 placebo mm @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
30.76 vs 28.46 placebo mm @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.29 vs 28.46 placebo mm @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.85 vs 26.22 placebo mm @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
37.95 vs 26.22 placebo mm @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
28.23 vs 28.25 placebo mm @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.55 vs 28.25 placebo mm @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
68.1 vs 61.67 placebo mm @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
27.66 vs 28.08 placebo mm @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
23.33 vs 24.15 placebo mm @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
Patient Global Assessment 33.59 mm @ 17.33wk5 mg
absolute value · mm
No placebo or comparator arm
NCT00814307 · Phase 3
show 13 more results
34.59 mm @ 21.67wk5 mg
NCT00814307 · Phase 3
32.56 mm @ 26wk5 mg
NCT00814307 · Phase 3
32.06 mm @ 39wk5 mg
NCT00856544 · Phase 3
30.64 mm @ 52wk5 mg
NCT00856544 · Phase 3
31.19 mm @ 39wk5 mg
NCT00847613 · Phase 3
31.77 mm @ 52wk5 mg
NCT00847613 · Phase 3
29.69 mm @ 17.33wk10 mg
NCT00814307 · Phase 3
29.37 mm @ 21.67wk10 mg
NCT00814307 · Phase 3
29.52 mm @ 26wk10 mg
NCT00814307 · Phase 3
28.01 mm @ 39wk10 mg
NCT00856544 · Phase 3
27.94 mm @ 52wk10 mg
NCT00856544 · Phase 3
28.05 mm @ 39wk10 mg
NCT00847613 · Phase 3
29.12 mm @ 52wk10 mg
NCT00847613 · Phase 3
Physician Global Assessment 43.43 vs 52.15 placebo mm @ 2wk5 mg
absolute value · mm
NCT00814307 · Phase 3
show 210 more results
35.89 vs 46.98 placebo mm @ 4.33wk5 mg
NCT00814307 · Phase 3
32.06 vs 44.45 placebo mm @ 8.67wk5 mg
NCT00814307 · Phase 3
29.2 vs 42.05 placebo mm @ 13wk5 mg
NCT00814307 · Phase 3
46.41 vs 49.08 placebo mm @ 2wk5 mg
NCT00856544 · Phase 3
38.35 vs 42.86 placebo mm @ 4.33wk5 mg
NCT00856544 · Phase 3
32.54 vs 41.25 placebo mm @ 8.67wk5 mg
NCT00856544 · Phase 3
31.97 vs 39.54 placebo mm @ 13wk5 mg
NCT00856544 · Phase 3
29.45 vs 33.04 placebo mm @ 19.5wk5 mg
NCT00856544 · Phase 3
25.83 vs 27.88 placebo mm @ 26wk5 mg
NCT00856544 · Phase 3
38.9 vs 50.73 placebo mm @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
30.28 vs 45.12 placebo mm @ 13wk5 mg twice daily
NCT00853385 · Phase 3
24.97 vs 29.76 placebo mm @ 26wk5 mg twice daily
NCT00853385 · Phase 3
19.93 vs 25.45 Adalimumab mm @ 39wk5 mg twice daily
NCT00853385 · Phase 3
18.67 vs 20.44 Adalimumab mm @ 52wk5 mg twice daily
NCT00853385 · Phase 3
37.97 vs 45.5 placebo mm @ 4.33wk5 mg
NCT00847613 · Phase 3
30.12 vs 43.29 placebo mm @ 13wk5 mg
NCT00847613 · Phase 3
25.47 vs 26.61 placebo mm @ 26wk5 mg
NCT00847613 · Phase 3
36.7 vs 45.52 MTX mm @ 4.33wk5 mg BID
NCT01039688 · Phase 3
27.84 vs 37.19 MTX mm @ 8.67wk5 mg BID
NCT01039688 · Phase 3
25.06 vs 32.07 MTX mm @ 13wk5 mg BID
NCT01039688 · Phase 3
22.19 vs 27.25 MTX mm @ 26wk5 mg BID
NCT01039688 · Phase 3
18.68 vs 23.65 MTX mm @ 39wk5 mg BID
NCT01039688 · Phase 3
17.63 vs 22.22 MTX mm @ 52wk5 mg BID
NCT01039688 · Phase 3
16.65 vs 23.29 MTX mm @ 65wk5 mg BID
NCT01039688 · Phase 3
16.47 vs 20.19 MTX mm @ 78wk5 mg BID
NCT01039688 · Phase 3
15.73 vs 20.01 MTX mm @ 91wk5 mg BID
NCT01039688 · Phase 3
15.31 vs 20.04 MTX mm @ 104wk5 mg BID
NCT01039688 · Phase 3
50.37 vs 55.19 placebo mm @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.3 vs 50.15 placebo mm @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.4 vs 46.12 placebo mm @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.79 vs 43.91 placebo mm @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.7 vs 44.83 placebo mm @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.8 vs 44.76 placebo mm @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.74 vs 28.7 placebo mm @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
27.04 vs 29.95 placebo mm @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.26 vs 24.05 placebo mm @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.26 vs 50.64 placebo mm @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
34.59 vs 44.62 placebo mm @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
24.67 vs 47.96 placebo mm @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.46 vs 40.21 placebo mm @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
13.71 vs 40.92 placebo mm @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.29 vs 49.05 placebo mm @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.73 vs 40.23 placebo mm @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
27.78 vs 37.85 placebo mm @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
27.26 vs 34.66 placebo mm @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.77 vs 35.7 placebo mm @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
23.67 vs 26.22 placebo mm @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
20.65 vs 21.95 placebo mm @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
16.91 vs 20.67 placebo mm @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
49.85 vs 55.54 placebo mm @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
41.65 vs 52.76 placebo mm @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
34.18 vs 46.01 placebo mm @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
31.42 vs 46.52 placebo mm @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
39.1 vs 42.04 placebo mm @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.47 vs 52.15 placebo mm @ 2wk10 mg
NCT00814307 · Phase 3
33.99 vs 46.98 placebo mm @ 4.33wk10 mg
NCT00814307 · Phase 3
26.75 vs 44.45 placebo mm @ 8.67wk10 mg
NCT00814307 · Phase 3
24.47 vs 42.05 placebo mm @ 13wk10 mg
NCT00814307 · Phase 3
43.79 vs 49.08 placebo mm @ 2wk10 mg
NCT00856544 · Phase 3
34.31 vs 42.86 placebo mm @ 4.33wk10 mg
NCT00856544 · Phase 3
29.4 vs 41.25 placebo mm @ 8.67wk10 mg
NCT00856544 · Phase 3
29.21 vs 39.54 placebo mm @ 13wk10 mg
NCT00856544 · Phase 3
26.11 vs 33.04 placebo mm @ 19.5wk10 mg
NCT00856544 · Phase 3
23.69 vs 27.88 placebo mm @ 26wk10 mg
NCT00856544 · Phase 3
36.16 vs 50.73 placebo mm @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
29.91 vs 45.12 placebo mm @ 13wk10 mg twice daily
NCT00853385 · Phase 3
24.46 vs 29.76 placebo mm @ 26wk10 mg twice daily
NCT00853385 · Phase 3
21.92 vs 25.45 Adalimumab mm @ 39wk10 mg twice daily
NCT00853385 · Phase 3
18.87 vs 20.44 Adalimumab mm @ 52wk10 mg twice daily
NCT00853385 · Phase 3
35.19 vs 45.5 placebo mm @ 4.33wk10 mg
NCT00847613 · Phase 3
24.47 vs 43.29 placebo mm @ 13wk10 mg
NCT00847613 · Phase 3
20.44 vs 26.61 placebo mm @ 26wk10 mg
NCT00847613 · Phase 3
33.05 vs 45.52 MTX mm @ 4.33wk10 mg BID
NCT01039688 · Phase 3
25.8 vs 37.19 MTX mm @ 8.67wk10 mg BID
NCT01039688 · Phase 3
22.8 vs 32.07 MTX mm @ 13wk10 mg BID
NCT01039688 · Phase 3
18.32 vs 27.25 MTX mm @ 26wk10 mg BID
NCT01039688 · Phase 3
16.61 vs 23.65 MTX mm @ 39wk10 mg BID
NCT01039688 · Phase 3
14.19 vs 22.22 MTX mm @ 52wk10 mg BID
NCT01039688 · Phase 3
14.97 vs 23.29 MTX mm @ 65wk10 mg BID
NCT01039688 · Phase 3
14.02 vs 20.19 MTX mm @ 78wk10 mg BID
NCT01039688 · Phase 3
14.61 vs 20.01 MTX mm @ 91wk10 mg BID
NCT01039688 · Phase 3
14.42 vs 20.04 MTX mm @ 104wk10 mg BID
NCT01039688 · Phase 3
39.85 vs 55.19 placebo mm @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.55 vs 50.15 placebo mm @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.22 vs 46.12 placebo mm @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.56 vs 43.91 placebo mm @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.72 vs 44.83 placebo mm @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
25.37 vs 44.76 placebo mm @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.39 vs 28.7 placebo mm @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
19.35 vs 29.95 placebo mm @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
20.13 vs 24.05 placebo mm @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
36.12 vs 50.64 placebo mm @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
28.84 vs 44.62 placebo mm @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
23.92 vs 47.96 placebo mm @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
16.57 vs 40.21 placebo mm @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
14.86 vs 40.92 placebo mm @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.85 vs 49.05 placebo mm @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.56 vs 40.23 placebo mm @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.82 vs 37.85 placebo mm @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.01 vs 34.66 placebo mm @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
26.47 vs 35.7 placebo mm @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
23 vs 26.22 placebo mm @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.05 vs 21.95 placebo mm @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
21.25 vs 20.67 placebo mm @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
36.3 vs 55.54 placebo mm @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
32.24 vs 52.76 placebo mm @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
23.91 vs 46.01 placebo mm @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
19.26 vs 46.52 placebo mm @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
26.24 vs 42.04 placebo mm @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
41.92 vs 49.05 placebo mm @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 49.05 placebo mm @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
32.96 vs 40.23 placebo mm @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 40.23 placebo mm @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
32.65 vs 37.85 placebo mm @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 37.85 placebo mm @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
27.7 vs 34.66 placebo mm @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 34.66 placebo mm @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
28.93 vs 35.7 placebo mm @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 35.7 placebo mm @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
18.6 vs 26.22 placebo mm @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
48.42 vs 26.22 placebo mm @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
18.84 vs 21.95 placebo mm @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
44.67 vs 21.95 placebo mm @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
14.49 vs 20.67 placebo mm @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
41 vs 20.67 placebo mm @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
44.98 vs 55.19 placebo mm @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.89 vs 50.15 placebo mm @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.56 vs 46.12 placebo mm @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
25.2 vs 43.91 placebo mm @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.68 vs 44.83 placebo mm @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.2 vs 44.76 placebo mm @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
21.09 vs 28.7 placebo mm @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
19.42 vs 29.95 placebo mm @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
19.06 vs 24.05 placebo mm @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35.99 vs 49.05 placebo mm @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.35 vs 40.23 placebo mm @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
27.08 vs 37.85 placebo mm @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
23.06 vs 34.66 placebo mm @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
23.28 vs 35.7 placebo mm @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
19.31 vs 26.22 placebo mm @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
16.19 vs 21.95 placebo mm @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
14.68 vs 20.67 placebo mm @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
37.8 vs 55.54 placebo mm @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
29.54 vs 52.76 placebo mm @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
27.45 vs 46.01 placebo mm @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
22.22 vs 46.52 placebo mm @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.78 vs 42.04 placebo mm @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
47.88 vs 55.19 placebo mm @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.23 vs 50.15 placebo mm @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.98 vs 46.12 placebo mm @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
36.54 vs 43.91 placebo mm @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
38.78 vs 44.83 placebo mm @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
36.65 vs 44.76 placebo mm @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
26.97 vs 28.7 placebo mm @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.86 vs 29.95 placebo mm @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
22.5 vs 24.05 placebo mm @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.96 vs 50.64 placebo mm @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.52 vs 44.62 placebo mm @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
33.04 vs 47.96 placebo mm @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
26.08 vs 40.21 placebo mm @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
23.38 vs 40.92 placebo mm @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
41.07 vs 49.05 placebo mm @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 49.05 placebo mm @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
36.92 vs 40.23 placebo mm @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 40.23 placebo mm @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.51 vs 37.85 placebo mm @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 37.85 placebo mm @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
26.6 vs 34.66 placebo mm @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 34.66 placebo mm @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
26.17 vs 35.7 placebo mm @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 35.7 placebo mm @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
19.77 vs 26.22 placebo mm @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.31 vs 26.22 placebo mm @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
20.91 vs 21.95 placebo mm @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
32.92 vs 21.95 placebo mm @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
20.26 vs 20.67 placebo mm @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
32.54 vs 20.67 placebo mm @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
52.3 vs 55.19 placebo mm @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.3 vs 50.15 placebo mm @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.75 vs 46.12 placebo mm @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
40.06 vs 43.91 placebo mm @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.65 vs 44.83 placebo mm @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.72 vs 44.76 placebo mm @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.93 vs 28.7 placebo mm @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
32.59 vs 29.95 placebo mm @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35.21 vs 24.05 placebo mm @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
49.96 vs 50.64 placebo mm @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
44.04 vs 44.62 placebo mm @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
41.3 vs 47.96 placebo mm @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
29.65 vs 40.21 placebo mm @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
26.31 vs 40.92 placebo mm @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
49.49 vs 49.05 placebo mm @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 49.05 placebo mm @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
41.69 vs 40.23 placebo mm @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 40.23 placebo mm @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
37.38 vs 37.85 placebo mm @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 37.85 placebo mm @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
35.71 vs 34.66 placebo mm @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 34.66 placebo mm @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
33.65 vs 35.7 placebo mm @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 35.7 placebo mm @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
23.95 vs 26.22 placebo mm @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
44.19 vs 26.22 placebo mm @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
20.44 vs 21.95 placebo mm @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.29 vs 21.95 placebo mm @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
18.9 vs 20.67 placebo mm @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
36.53 vs 20.67 placebo mm @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
63.28 vs 65.38 placebo mm @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
30.8 vs 31.85 placebo mm @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
24.3 vs 29.7 placebo mm @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination

+ 654 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · tofacitinib's landscape